



Marine life as a source for breast cancer treatment: A comprehensive review

Amjad Hussain, Marie-Lise Bourguet-Kondracki, Maryam Majeed, Muhammad Ibrahim, Muhammad Imran, Xian-Wen Yang, Ishtiaq Ahmed, Ataf Ali Altaf, Anees Ahmed Khalil, Abdur Rauf, et al.

► To cite this version:

Amjad Hussain, Marie-Lise Bourguet-Kondracki, Maryam Majeed, Muhammad Ibrahim, Muhammad Imran, et al.. Marine life as a source for breast cancer treatment: A comprehensive review. *Biomedicine and Pharmacotherapy*, 2023, 159, pp.114165. 10.1016/j.biopha.2022.114165 . hal-04337880


HAL Id: hal-04337880

<https://hal.science/hal-04337880v1>

Submitted on 22 Feb 2024

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Review

Marine life as a source for breast cancer treatment: A comprehensive review



Amjad Hussain ^{a,b,*¹}, Marie-Lise Bourguet-Kondracki ^b, Maryam Majeed ^c, Muhammad Ibrahim ^c, Muhammad Imran ^d, Xian-Wen Yang ^e, Ishtiaq Ahmed ^f, Ataf Ali Altaf ^a, Anees Ahmed Khalil ^g, Abdur Rauf ^h, Polrat Wilairatana ^{i,**¹}, Hassan A. Hemeg ^o, Riaz Ullah ^j, Ivan R. Green ^k, Iftikhar Ali ^l, Syed Tasadaque A. Shah ^m, Hidayat Hussain ^{n,**}

^a Department of Chemistry University of Okara, Okara, Pakistan^b Laboratoire Molécules de Communication et Adaptation des Micro-organismes, UMR 7245 MNHN-CNRS, Muséum National d'Histoire Naturelle, 57 rue Cuvier (C.P. 54), 75005 Paris, France^c Department of Applied Chemistry, Government College University, Faisalabad, Pakistan^d Department of chemistry, Faculty of Science, Research center for Advanced Materials Science (RCAMS), King Khalid University, P.O. Box 9004, Abha 61413, Saudi Arabia^e Key Laboratory of Marine Biogenic Resources, Third Institute of Oceanography, Ministry of Natural Resources, 184 Daxue Road, Xiamen 361005, China^f Department of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge, UK^g University Institute of Diet and Nutritional Sciences, Faculty of Allied Health Sciences, The University of Lahore, Pakistan^h Department of Chemistry, University of Swabi Khyber Pakhtunkhwa, Pakistanⁱ Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, Bangkok 10400, Thailand^j Department of Pharmacognosy, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia^k Department of Chemistry and Polymer Science, University of Stellenbosch, Private Bag X1, Matieland, Stellenbosch 7600, South Africa^l Department of Chemistry, Karakoram International University, Gilgit 15100, Pakistan^m Department of Education, Sukkur IBA University, Sukkur 65200, Sindh, Pakistanⁿ Leibniz Institute of Plant Biochemistry, Department of Bioorganic Chemistry, Weinberg 3, D-06120 Halle (Saale), Germany^o Department of Medical Laboratory Technology, College of Applied Medical Sciences, Taibah University, Al-Medinah Al-Monawara, Saudi Arabia

ARTICLE INFO

ABSTRACT

Keywords:

Breast cancer

Marine natural products

Sponges

Cyanobacteria

Fungi

Algae

Tunicates

Actinomycetes

Ascidians

Breast cancer, one of the most significant tumors among all cancer cells, still has deficiencies for effective treatment. Moreover, substitute treatments employing natural products as bioactive metabolites has been seriously considered. The source of bioactive metabolites are not only the most numerous but also represent the richest source. A unique source is from the oceans or marine species which demonstrated intriguing chemical and biological diversity which represents an astonishing reserve for discovering novel anticancer drugs. Notably, marine sponges produce the largest amount of diverse bioactive peptides, alkaloids, terpenoids, polyketides along with many secondary metabolites whose potential is mostly therapeutic. In this review, our main focus is on the marine derived secondary metabolites which demonstrated cytotoxic effects towards numerous breast cancer cells and have been isolated from the marine sources such as marine sponges, cyanobacteria, fungi, algae, tunicates, actinomycetes, ascidians, and other sources of marine organisms.

1. Introduction



The development of modern pharmaceuticals represents one of the major challenges of this century. Drugs like penicillin, streptomycin, and vincristine, among others, have largely contributed to the control of

human disease since their discovery early in the 20th century. Novel treatments have enhanced the life expectancy of people and improved their standard of living. Society has become increasingly dependent on the availability of effective and safe pharmaceutical drugs for this improved societal development. Almost 50% of the drugs are either

* Corresponding author at: Department of Chemistry University of Okara, Okara, Pakistan.

** Corresponding authors.

E-mail addresses: amjadhussain@uo.edu.pk (A. Hussain), polrat.wil@mahidol.ac.th (P. Wilairatana), Hussainchem3@gmail.com, Hidayat.Hussain@ipb-halle.de (H. Hussain).¹ Equally contributed.

**Fig. 1.** Structures of guanidine alkaloids 1–5.**Fig. 2.** Structures of guanidine alkaloids 6–17.

extracted from natural sources or manufactured by employing natural products as scaffolds or initiative materials. These natural products have a remarkable chemical variety that has progressed over thousands of years, resulting in a marvellous diversity in their pharmacological processes and drug-like qualities [1–3].

The marine environment has become a rich target for discovering

natural drugs due to the comparatively undiscovered biodiversity compared to terrestrial environments. The Ocean's world, with its 70% coverage of the global surface makes 95% of the total biosphere to potentially provide a great source of bioactive natural compounds [3,4]. Marine organisms are a tremendous resource of marine natural products (MNPs) which can be employed to treat life-threatening diseases




Fig. 3. Structures of alkaloids 18–24.

such as cancer [3,4]. So far, over 30,000 marine natural products have been isolated from the marine world [5]. Due to this exceptional diversity in varied chemical skeletons/scaffolds produced by marine organisms and microorganisms, the marine biosphere field is considered as the largest potential reservoir of bioactive natural products, able to offer a huge variety of active drugs [3,4].

There are some examples of approved anticancer therapeutic agents which can be considered analogs of MNPs. The anticancer drugs cytarabine (ara-C), and ecteinascidin 743 which were isolated from tunicate *Ecteinascidia turbinata*. Another example is eribulin mesylate which is a synthetic analog of the MNP halichondrin B. Another approved anti-cancer drug is brentuximab vedotin an antibody–drug conjugate (ADC), comprising of a tumor-specific antibody and the dolastatin 10 derivatives named monomethyl auristatin E [4]. Breast cancer is one of the most serious causes of death in women worldwide, especially in developed countries, and its occurrence is increasing. Breast cancer is a very common type of cancer and ~2–2.5 million cases are detected globally in women each year. An interesting statistic is that ~627,000 women died in 2018 due to breast cancer [6].

Regarding actual clinical trials, more than 50% of drugs are obtained directly from nature or are derivatives of natural products. To date, nature has provided almost 60% of approved drugs for cancer treatment or management. The marine world, more recently explored, is a most challenging source for investigations, offering new pathways of promising molecule development with anti-mammary activities. Quite recently Ahmed et al. [7] published a review about marine peptides used for the treatment of breast cancer and in 2014 Kalimuthu et al. [8] in their review covered only around thirty marine derived natural products which illustrated anticancer effects towards breast and prostate cancer cells. This current review deals with an overview of potential secondary metabolites which demonstrate cytotoxicity towards numerous breast cancer cells and which are isolated from marine sources such as marine sponges, marine seaweeds, tunics, marine bacteria, and fungi covering a reasonable period up to December 2021.

2. Marine sponges

2.1. Alkaloids

2.1.1. Guanidine alkaloids

Monanchomycalin C (1) and the previously identified ptilomycalin (2) (Fig. 1) are both pentacyclic guanidine alkaloids obtained from the far-eastern sponge *Monanchora pulchra*. Compounds 1 and 2 possessed cytotoxic effects towards the MDA-MB-231 with IC₅₀: of 8.2 μM and 4.3 μM , respectively [9]. Netamines C (3) and D (4) are also guanidine alkaloids which were produced by marine sponge *Bienna laboutei* and these compounds revealed cytotoxicity against the human breast MDA-MB-231 cell line with GI₅₀ values of 2.6 μM and 6.3 μM , respectively [10].

Crambescidin 800 (5) belongs to the chemical class of guanidine alkaloids produced by the marine-derived sponge *Monanchora Viridis*. This compound 5 illustrated potent cytotoxic effects towards various triple negative breast cancer cells. Notably, 5 showed potent effects towards T11 and SUM159PT cells with IC₅₀ values: 0.07 and 0.59 μM (72 h), respectively. Interestingly, the cytotoxic effects of this alkaloid was higher (against T11 cells) than the standard cisplatin (IC₅₀: 0.70 μM) and 5-Fluorouracil (IC₅₀: 0.87 μM) [11].

2.1.2. Indole alkaloids

Damirine A (6) (Fig. 2) was produced by sponge *Damiria* sp. and demonstrated significant cytotoxicity towards MDA-MB-468 with GI₅₀ = 2.0 μM [12]. 3,3'-BIEA (7) was isolated from sponge *Gellius* sp. and possessed cytotoxic effects towards MCF-7, MDA-MB-231 and VERO cells with IC₅₀: 3.4, 3.4, and 3.8 μM respectively [13]. Dragmacidins A (8), B (9), I (10) and J (11) were produced by sponge *Dragmacidon* sp. Compounds 8, 10, 11 showed significant cytotoxic effects towards MDA-MB-231 with IC₅₀: 3.8, 4.7, and 7.5 μM respectively while the IC₅₀ of 16 was 28.0 μM [14]. Capon et al. [15] reported trachycladindoles A–F (12–17) from marine sponge *Trachycladus laevipirulifer*. Interesting all compounds (except alkaloid 14) possessed significant cytotoxic effects towards MDA-MB-231 with GI₅₀ < 3 μM .


Table 1
Compounds 1–94 having anti-breast cancer properties.

| Name | Organism | Cell line | Cytotoxicity | Ref. |
|--|--------------------------------------|-----------------------------|--|---------|
| Monanchomycalin C (1) | <i>Monanchora pulchra</i> | MDA-MB-231 | IC ₅₀ : 8.2 μM | [9] |
| Ptilomycalin (2) | <i>Monanchora pulchra</i> | MDA-MB-231 | IC ₅₀ : 4.3 μM | [9] |
| Netamine C (3) | <i>Bienna laboutei</i> | MDA-MB-231 | GI ₅₀ : 2.6 μM | [10] |
| Netamine D (4) | <i>Bienna laboutei</i> | MDA-MB-231 | GI ₅₀ : 6.3 μM | [10] |
| Crambescidin 800 (5) | <i>Monanchora Viridis</i> | T11 SUM159PT | IC ₅₀ : 0.07 μM IC ₅₀ : 0.59 μM | [11] |
| Damirine A (6) | <i>Damiria</i> sp. | MDA-MB-231 | GI ₅₀ : 2.0 μM | [12] |
| 3,3'-BIEA (7) | <i>Gellius</i> sp. | MCF-7 | IC ₅₀ : 3.4 μM | [13] |
| Dragmacidin A (8) | <i>Dragmacidon</i> sp. | MDA-MB-231 | IC ₅₀ : 3.4 μM | [14] |
| Dragmacidin B (9) | <i>Dragmacidon</i> sp. | MDA-MB-231 | IC ₅₀ : 28.0 μM | [14] |
| Dragmacidin I (10) | <i>Dragmacidon</i> sp. | MDA-MB-231 | IC ₅₀ : 4.7 μM | [14] |
| Dragmacidin J (11) | <i>Dragmacidon</i> sp. | MDA-MB-231 | IC ₅₀ : 7.5 μM | [14] |
| Trachycladindoles A (12) | <i>Trachycladus laevispirulifer</i> | MDA-MB-231 | GI ₅₀ : 1.2 μM | [15] |
| Trachycladindoles B (13) | <i>Trachycladus laevispirulifer</i> | MDA-MB-231 | GI ₅₀ : 2.7 μM | [15] |
| Trachycladindoles C (14) | <i>Trachycladus laevispirulifer</i> | MDA-MB-231 | GI ₅₀ : 12.2 μM | [15] |
| Trachycladindoles D (15) | <i>Trachycladus laevispirulifer</i> | MDA-MB-231 | GI ₅₀ : 2.4 μM | [15] |
| Trachycladindoles E (16) | <i>Trachycladus laevispirulifer</i> | MDA-MB-231 | GI ₅₀ : 1.1 μM | [15] |
| Trachycladindoles F (17) | <i>Trachycladus laevispirulifer</i> | MDA-MB-231 | GI ₅₀ : 2.3 μM | [15] |
| Kuanoniamines A (18) | <i>Oceanapia Sagittaria</i> | MCF-7 | GI ₅₀ : 0.81 μM; GI ₅₀ : 10.23 μM | [16] |
| Kuanoniamine C (19) | <i>Oceanapia Sagittaria</i> | MDA-MB-231 | GI ₅₀ : 0.12 μM; GI ₅₀ : 0.73 μM | [16] |
| 7-Hydroxyneolamellarin A (20) | <i>Dendrilla nigra</i> | Human T-47D | IC ₅₀ : 1.9 μM | [17] |
| Neopetrosiamine A (21) | <i>Neopetrosia proxima</i> | MCF-7 | IC ₅₀ : 3.5 μM | [18] |
| Renieramycin M (22) | <i>Xestospongia</i> sp. | MDA-MB-231 | IC ₅₀ : 3.8 nM | [19,20] |
| Debromohymenialdisine (DBH) (23) | <i>Stylixa flabeliformis</i> | MCF-7 | IC ₅₀ : 25 mM | [21] |
| 2,3-Dihydro-2,3-dioxo aaptamine (24) | <i>Aaptos aaptos</i> | MCF-7 | IC ₅₀ : 40.7 μM | [22] |
| Microcionamides A (25) | <i>Clathria (Thalysias) abietina</i> | MCF-7 SKBR-3 | IC ₅₀ : 125 nM IC ₅₀ : 98 nM | [23] |
| Microcionamides B (26) | <i>Clathria (Thalysias) abietina</i> | MCF-7 SKBR-3 | IC ₅₀ : 177 nM IC ₅₀ : 172 nM | [23] |
| Pembamide (27) | <i>Cribrochalina</i> sp. | MDA-MB-231 | GI ₅₀ : 3.35 μM | [24] |
| Pipecolidepsin A (28) | <i>Homophymia lamellose</i> | MDA-MB-231 | GI ₅₀ : 0.7 μM | [25] |
| Pipecolidepsin B (29) | <i>Homophymia lamellose</i> | MDA-MB-231 | GI ₅₀ : 0.2 μM | [25] |
| Stylopeptide 2 (30) | <i>Stylotella</i> sp. | BT-549 | Inhibition: 23% | [26] |
| Stylopeptide 2 (30) | <i>Stylotella</i> sp. | HS 578 T | Inhibition: 44% | [26] |
| Hemiassterlin A (31) | <i>Cymbastela</i> sp. | MCF-7 | ED ₅₀ : 0.089 μg/mL | [27] |
| Hemiassterlin B (32) | <i>Cymbastela</i> sp. | MCF-7 | ED ₅₀ : 0.066 μg/mL | [27] |
| Criamide B (33) | <i>Cymbastela</i> sp. | MCF-7 | ED ₅₀ : 6.8 μg/mL | [27] |
| Motuporin (34) | <i>Theonella swinhonis</i> | MCF-7 | IC ₅₀ : 12.4 μg/mL | [28] |
| Geodiamolides A (35), B (36), and H (37) | <i>Geodia</i> sp. | MCF-7, T47D | ED ₅₀ : 9.82–620 nM | [29] |
| Cyclo(L-leucyl-L-prolyl) (CLP) (38) | <i>Rhaphisia pallida</i> | MDA-MB-231 MDA-MB-468 | IC ₅₀ : 73.4 μM IC ₅₀ : 67.4 μM | [32] |
| Styliassin B (39) | <i>Stylixa massa</i> | MCF-7 | IC ₅₀ : 4.8 μM | [33] |
| Scleritodermin A (40) | <i>Scleritoderma nodosum</i> | SKBR3 | IC ₅₀ : 0.670 μM | [34] |
| Compounds 41–44 | <i>Lendenfeldia</i> sp. | MCF-7, MDA-MB-231, and T47D | IC ₅₀ : 0.2–29 μM | [35] |
| Thorectandrol A (45) | <i>Thorectandra</i> sp | MCF-7 | IC ₅₀ : 40.0 μg/mL | [36,37] |
| Thorectandrol B (46) | <i>Thorectandra</i> sp | MCF-7 | IC ₅₀ : 30.0 μg/mL | [36,37] |
| palaualol (47) | <i>Thorectandra</i> sp | MCF-7 | IC ₅₀ : 14.0 μg/mL | [36,37] |
| Sesterterpenoids 48–59 | <i>Dysidea</i> sp. | MDA-MB-231 | IC ₅₀ : 4.2–72.4 μM | [38] |
| Sipholane A (60) | <i>Callyspongia siphonella</i> | MDA-MB-231 | IC ₅₀ : 37.5 μM | [39] |
| Sipholenone A (61) | <i>Callyspongia siphonella</i> | MDA-MB-231 | IC ₅₀ : 28.1 μM | [39] |
| 3-epi-sodwanone K 3-acetate (63) | <i>Axinella</i> sp. | T47D | IC ₅₀ : 22 μM | [41] |
| Sodwanones V (64) | <i>Axinella</i> sp. | MDA-MB-231 | IC ₅₀ : 23 μM | [41] |
| Dolabellane diterpene, 6,10,18-triacetoxy-2E,7E-dolabelladien (65) | <i>Luffariella variabilis</i> | MDA-MB-231 | IC ₅₀ : 11.5 μM | [42] |
| Metachromin U (66) | <i>Thorecta reticulata</i> | MCF-7 | GI ₅₀ : 29 μM | [43] |
| Metachromin V (67) | <i>Thorecta reticulata</i> | MCF-7 | GI ₅₀ : 3.2 μM | [43] |
| Metachromin W (68) | <i>Thorecta reticulata</i> | MCF-7 | GI ₅₀ : 107 μM | [43] |
| 3'-Aminoavarone (69) | <i>Dysidea</i> sp. | MCF-7-MB-231 | IC ₅₀ : 2.0 μg/mL | [44] |
| Liphagal (70) | <i>Aka coralliphaga</i> | MDA-468 | IC ₅₀ : 1.58 μM | [45,46] |
| Aplysamine-2 (71) | <i>Pseudoceratina purpurea</i> | MCF-7 | IC ₅₀ : 25.7 μM | [47] |
| E,Z)-Psammaphlin A (72) | <i>Dendrilla lacunose</i> | MDA-MB-231 | IC ₅₀ : 0.019 μM | [48] |
| Psammaphlin E (73) | <i>Dendrilla lacunose</i> | MDA-MB-231 | IC ₅₀ : 0.257 μM | [48] |
| E,E)-Psammaphlin K (74) | <i>Dendrilla lacunose</i> | MDA-MB-231 | IC ₅₀ : 0.038 μM | [48] |
| (E,E)-Psammaphlin A (75) | <i>Dendrilla lacunose</i> | MDA-MB-231 | IC ₅₀ : 0.037 μM | [48] |
| Bisaprasin (76) | <i>Dendrilla lacunose</i> | MDA-MB-231 | IC ₅₀ : 0.948 μM | [48] |
| Aragusterol A (YTA0040) (77) | <i>Xestospongia</i> | MCF-7 | IC ₅₀ : 0.28 nM | [49] |
| Dictyostatin-1 (78) | <i>Spongia</i> sp. | MCF-7 | IC ₅₀ : 1.5 nM | [50] |
| Peloruside A (79) | <i>Mycale hentscheli</i> | MDA-MB-231 | IC ₅₀ : 3.8 nM | [51] |
| Hemimycalins C (80) | <i>Hemimycale</i> sp. | MDA-MB-231 | IC ₅₀ : 28.5, μM | [52] |
| Hemimycalins D (81) | <i>Hemimycale</i> sp. | MDA-MB-231 | IC ₅₀ : 31.7, μM | [52] |
| Hemimycalins E (82) | <i>Hemimycale</i> sp. | MDA-MB-231 | IC ₅₀ : 21.5 μM | [52] |
| Hippotulosas A (83) | <i>Hippopongia fistulosa</i> | MCF-7 | IC ₅₀ : 75.6 μM | [53] |

(continued on next page)

Table 1 (continued)

| Name | Organism | Cell line | Cytotoxicity | Ref. |
|--|-------------------------------|------------|--------------------------|------|
| Furospinulosin-1 (84) | <i>Hippospongia fistulosa</i> | MCF-7 | IC_{50} : 86.9 μ M | [53] |
| 13-Apoastaxanthinone (85) | <i>Clathria reinwardti</i> | MCF-7 | IC_{50} : 79.2 μ M | [54] |
| 9-apoastaxanthinone (86) | <i>Clathria reinwardti</i> | MCF-7 | IC_{50} : 84.4 μ M | [54] |
| 2,3-Dehydro-4-oxo- β -Ionone (87), | <i>Clathria reinwardti</i> | MCF-7 | IC_{50} : 75.7 μ M | [54] |
| 9 4-(2',3',4'-Trimethylphenyl)-but-3(<i>E</i>)-en-2-one (88) | <i>Clathria reinwardti</i> | MCF-7 | IC_{50} : 33.1 μ M | [54] |
| 22,23-dihydro-24-nordankasterone A (89) | <i>Luffariella variabilis</i> | MDA-MB-231 | IC_{50} : 7.4 μ M | [45] |
| Steroid 90 | <i>Phyllospongia sp.</i> | MCF-7 | IC_{50} : 8.8 μ M | [55] |
| Steroid 91 | <i>Phyllospongia sp.</i> | MCF-7 | IC_{50} : 10.3 μ M | [55] |
| Steroid 92 | <i>Phyllospongia sp.</i> | MCF-7 | IC_{50} : 36.5 μ M | [55] |
| Steroid 93 | <i>Phyllospongia sp.</i> | MCF-7 | IC_{50} : 47.1 μ M | [55] |
| Steroid 94 | <i>Phyllospongia sp.</i> | MCF-7 | IC_{50} : 3.9 μ M | [55] |

**Fig. 4.** Structures of peptides 25–30.

2.1.3. Miscellaneous alkaloids

Kuanoniamines A (18) and C (19) (Fig. 3) represent pyridoacridine alkaloids that were isolated from marine sponge *Oceanapia Sagittaria* (Sollas). Kuanoniamine A (18) revealed inhibitory activity against the growth of MCF-7 and MDA-MB-231 cell lines with GI_{50} : 0.81 ± 0.11 and $10.23 \pm 3.35 \mu$ M, respectively. Kuanoniamine C (19), although less effective, showed a higher selectivity against the MCF-7 and MDA-MB-231 cells with GI_{50} : 0.12 ± 0.07 and $0.73 \pm 0.27 \mu$ M, respectively [16]. 7-Hydroxyneolamellarin A (20) is a lamellarin-like phenolic pyrrole purified from the marine sponge *Dendrilla nigra* and was shown to prevent hypoxia-induced HIF-1 stimulation and hypoxia-induced vascular endothelial growth factor (VEGF) initiation in the human T47D cell line with an IC_{50} : 1.9μ M [17]. Neopetrosiamine A (21) is another tetracyclic

bis-piperidine alkaloid produced by sponge *Neopetrosia proxima*, collected from the western side of the beach Puerto Rico. Compound 8 possesses resilient inhibitory activity against MCF-7 with an IC_{50} : 3.5μ M [18].

Renieramycin M (22) (Fig. 3) is a tetrahydroisoquinoline reported from the blue sponge *Xestospongia* sp. [19]. Compound 22 displayed cytotoxic activity against human MDA-MB-231 cell lines with an IC_{50} value of 3.8 nM [20]. Debromohymenialdisine (DBH) (23) was produced by the marine sponge *Styliasa flabeliformis*, collected from Motupore Island in Papua New Guinea. DBH also showed moderate cytotoxicity towards MCF-7 cancer cell lines with an IC_{50} value of 25 mM . In association with radiotherapy, DBH at a non-cytotoxic concentration of 3μ M was shown to reduce pCHK1/2 expression and




Fig. 5. Structures of peptides 31–37.




Fig. 6. Structures of peptides 38–40.

proliferation in MCF-7 breast cancer cells. It also decreased the growth rates of stem cell cancer in a time-dependent manner [21]. On the other hand, 2,3-dihydro-2,3-dioxo aaptamine (24) showed activity against MCF-7 with IC₅₀: 40.7 μM (Table 1) and this compound was produced by Sponge *Aaptos aaptos* [22].

2.2. Peptides

The two linear peptides microcionamides A (25) and B (26) (Fig. 4), were produced by sponge *Clathria (Thalysias) abietina* reported from the coastline of the Philippines. These geometric isomeric peptides 25 and 26 displayed potential cytotoxicity towards MCF-7 with IC₅₀: 125 and 177 nM, respectively. In addition peptides 25 and 26 demonstrated significant effects against SKBR-3 with IC₅₀: 98 and 172 nM, respectively. Notably, the effects of these peptides towards MCF-7 were higher than standard doxorubicin (IC₅₀: 257 nM) [23]. Pembamide (27) is

produced by the marine sponge *Cribrochalina* sp. and possesses potent cytotoxicity against MDA-MB-231 with a GI₅₀: 3.35 μM [24]. In another report, pipecolidepsin A (28) and B (29) were described as being isolated from the marine sponge *Homophymia lamellose* and displayed potent cytotoxic effects against MDA-MB-231 with a GI₅₀: 0.7 and 0.2 μM, respectively [25]. The cycloheptapeptide, stylopeptide 2 (30) was isolated from the marine sponge *Stylophora* sp. and illustrated cytotoxicity against BT-549 and HS 578 T with growth inhibition of 77% and 56%, respectively [26].

Hemasterlin A (31), B (32), and criamide B (33) (Fig. 5) were produced by the marine sponge *Cymbastela* sp. Notably, peptides 31–33 displayed potent cytotoxicity against MCF-7 with the ED₅₀: values of 0.089, 0.066, and 6.8 μg/mL respectively [27]. Motuporin (34), a cytotoxin was produced by sponge *Theonella swinhonis* and exhibited cytotoxicity towards MCF-7 with IC₅₀: 12.4 μg/mL [28]. Another series of cyclic depsipeptides known as geodiamolides A (35), B (36), and H (37) were isolated from the Caribbean sponges *Geodia* sp. All these peptides were significantly active towards T47D and MCF-7 with EC₅₀ ranging from 9.82 to 620 nM. Compounds 35 and 37 were active against T47D cells with EC₅₀ values of 18.82 and 38.36 nM, respectively. In addition, peptides 35 and 37 revealed a strong activity against MCF-7 cancer cell lines with EC₅₀ values of 17.83 and 9.82 nM, respectively [29]. In another study, geodiamolide H (37) was also shown to be active against MDA-MB-231/ATCC with TGI: 4.33 × 10⁻⁷ M [30].

Cyclo(L-leucyl-L-prolyl) (CLP, 38) (Fig. 6) is a homo-detic cyclic peptide, isolated from the marine sponge *Raphisia pallida* [31] and exhibited an anti-propagative cytotoxic effect towards human the triple-negative breast cancers MDA-MB-231 and MDA-MB-468 with IC₅₀ values of 73.4 and 67.4 μM, respectively [32]. It has confirmed that 38 induced cell cycle arrest with the result of reducing the expression of cyclins D₁, CDK4, PAK, Rac₁, and p27kip₁, suggesting a mechanism of action through EGFR and CD151 signaling pathways [32]. Styllissatin B (39) is a heptapeptide produced by marine sponge *Styliissa massa*, which




Fig. 7. Structures of Sesterterpenes 41–59.

demonstrated inhibitory effects towards MCF-7 with an IC₅₀ value of 4.8 μM [33]. Scleritodermin A (40) is a cyclic peptide isolated from the lithistid sponge *Scleritoderma nodosum*, was highly cytotoxic against the human breast SKBR3 cancer cell line with an IC₅₀ value of 0.670 μM [34].

2.3. Terpenes

2.3.1. Sesterterpenes

Furosgonolide (41) (Fig. 7), a furanolipid-type terpene, together with the sesterterpenes 22-hydroxy-24-methyl-12α-hydroxy-24-

oxoscalar-16-en-25-al (42), 24-methyl-12,24,25-trioxoscalar-16-en-22-oate (43) and 22-hydroxy-24-methyl-12,24-dioxoscalar-16-en-25-al (44) were isolated from the marine sponge *Lendenfeldia* sp., collected off the islands of the State of the Northern Mariana [35]. These compounds were evaluated for their hypoxia-inducible factor-1 (HIF-1) inhibitory activity and tumor cell lines cytotoxicity. The HIF-1 transcription factor is a heterodimer constituted of two sub-units HIF-1α and ARNT1/HIF-1β. Terpenes 41–44 were tested towards the MCF-7, MDA-MB-231, and T47D cells proliferation in normoxic hypoxic (Hyp, 1% O₂) and normal (95% air) conditions and revealed IC₅₀ values ranging from 0.2 to 29 μM [35].





Fig. 8. Structures of Diterpenes and triterpenes 60–65.




Fig. 9. Structures of Meroterpenoids 66–70.

Thorectandrols A (**45**), B (**46**), and palauolol (**47**), sesterterpenoids containing a bicarbocyclic frame, were identified from a marine Palauan sponge *Thorectandra* sp. Thorectandrols A (**45**) and B (**46**) displayed good cytotoxicity towards the MCF-7 cell line with IC₅₀: 40.0 and 30.0 µg/mL, respectively. It is interesting to note that compound **47** displayed better effects than metabolites **45** and **46** with an IC₅₀ value of 14.0 µg/mL [36,37]. Sesterterpenoids 48–59, were produced by sponge *Dysidea* sp. and possessed cytotoxicity towards MDA-MB-231 with IC₅₀ ranging from 4.2 and 72.4 µM respectively. Notably compound **65** was the most potent against MDA-MB-231 with IC₅₀: 4.2 µM [38].

2.3.2. Diterpenes and triterpenes

Sipholane A (**60**) and sipholenone A (**61**) are unusual cyclized triterpenes isolated from the Red Sea sponge *Callyspongia siphonella* (Fig. 8). Compounds **60** and **61** showed mild cytotoxicity against the metastatic human breast MDA-MB-231 cancer cell line, demonstrating

IC₅₀ values of 37.5 and 28.1 µM, respectively [39]. Flabellatene A (**62**), a diterpene isolated from the marine sponge *Lissodendoryx flabellata*, illustrated anti-proliferative effects against MCF-7 in a dose-dependent manner [40]. The marine sponge *Axinella* sp. produced sodwanone triterpenes named 3-epi-sodwanone K 3-acetate (**63**) and sodwanones V (**64**). Triterpene **63** displayed cytotoxic effects towards T47D cell with IC₅₀: 22 µM while **64** showed inhibited MDA-MB-231 with an IC₅₀: 23 µM [41]. Dolabellane diterpene, 6,10,18-triacetoxy-2E,7E-dolabelladien (**65**) was produced by sponge *Luffariella variabilis* and demonstrated cytotoxicity towards MDA-MB-231 with IC₅₀: 11.5 µM [42].

2.3.3. Meroterpenoids

Metachromins U-W (**66**–**68**) (Fig. 9) are merosesquiterpenoids isolated from the marine sponge *Thorecta reticulata*. Metachromin V (**67**) illustrated cytotoxicity towards the MCF-7 cell line with a GI₅₀: 3.2 µM, while compounds **66** and **68** showed lower potent activity with GI₅₀:




Fig. 10. Structures of bromotyrosine and psammaphlin derivatives 71–76.




Fig. 11. Structures of miscellaneous compounds 77–84.




Fig. 12. Structures of miscellaneous compounds 85–94.




Fig. 13. Structures of polysaccharides 95–97.

values of 29 and 107 μM , respectively [43]. Meroterpene, 3'-amino-avarone (69), is produced by the marine sponge *Dysidea* sp. and inhibited the MDA-MB-231 cancer cell with an IC₅₀ of 2 $\mu\text{g}/\text{mL}$ [44]. The meroterpene liphagal (70) was produced by marine sponge *Aka coralliphaga* collected off the Dominican coast [45]. Liphagal (70) showed cytotoxic effects towards the MDA-468 cell line with an IC₅₀: 1.58 μM [46].

2.4. Bromotyrosine and psammaplin derivatives

The bromotyrosine derivative aplysamine-2 (71) (Fig. 10), was produced by marine sponge *Pseudoceratina purpurea*. This compound displayed cytotoxicity against MCF-7 with an IC₅₀ value of 25.7 μM [47]. Five known compounds viz. (E,Z)-psammaplin A (72), psammaplin E (73), (E,E)-psammaplin K (74), (E,E)-psammaplin A (75), and bisaprasin (76) were obtained from the marine sponge *Dendrilla lacunose*. Compounds 72–76 illustrated potent activity against the MDA-MB-231-derived organotropic subclones with IC₅₀: 0.019, 0.257, 0.038, 0.037, and 0.948 μM , respectively [48].

2.5. Miscellaneous

Aragusterol A (YTA0040) (77) (Fig. 11), a steroid obtained from marine sponge *Xestospongia* collected from Okinawan, showed potent potential towards MCF-7 with an IC₅₀: 0.28 nM [49]. Dictyostatin-1 (78) is a macrocyclic lactone from the Republic of the Maldives and was identified from a marine sponge *Spongia* sp. Compound 78 showed effective activity against MCF-7 cell lines with IC₅₀: 1.5 nM [50]. The polyketide peloruside A (79) isolated from the marine sponge *Mycale hentscheli* possesses a non-toxoid and specific binding site. This molecule possessed effects towards MCF-7 cancer cell line, possessing an IC₅₀ value of 3.8 nM and blocking the G₂/M at 25 nM. Compound 79 was shown to reduce the average growth rate and length of the tumor by 24% and 41%, respectively [51]. Hemimycalins C–E (80–82) were produced by sponge *Hemimycale* sp. and demonstrated cytotoxicity




Fig. 14. Structures of sesquiterpenes and monoterpenes 98–103.




Fig. 15. Structures of Meroterpenoids and Diterpenes 104–111.




Fig. 16. Structures of Miscellaneous compounds 112–116.

towards MDA-MB-231 with IC₅₀: 28.5, 31.7, and 21.5 μM , respectively [52]. In another study, hippotulosas A (83) and furospinulosin-1 (84) were produced by sponge *Hippospongia fistulosa* and both compounds possessed cytotoxic effects towards MCF-7 as 75.6 and 86.9 μM , respectively [53].

13-Apoastaxanthinone (85), 9-apoastaxanthinone (86), 2,3-dehydro-4-oxo- β -Ionone (87), and 4-(2',3',4'-trimethylphenyl)-but-3(*E*)-en-2-one (88) were reported from Sponge *Clathria reinwardti* and demonstrated cytotoxicity towards MCF-7 with IC₅₀: 79.2, 84.4, 75.7 and 33.1 μM respectively [54]. Steroid, 22,23-dihydro-24-nordankasterone




Fig. 18. Structures of peptides 120–126.

A (89) was produced by sponge *Luffariella variabilis* and demonstrated cytotoxicity towards MDA-MB-231 with IC_{50} : 7.4 μM [45]. Steroids 90–94 were reported from sponge *Phyllospongia* sp. and showed activities towards MCF-7 with IC_{50} : 8.8, 10.3, 36.5, 47.1, and 3.9 μM respectively [55] (Fig. 12).

3. Marine seaweeds or algae

3.1. Polysaccharides

The polysaccharide 95 (Fig. 13) isolated from the green algae *Ulva lactuca*, has been proven to possess *in vivo* and *in vitro* anti-breast cancer activity. In human MCF-7 cancer cells, compound 95 showed an inhibitory effect with an IC_{50} value of 224.716 $\mu\text{g}/\text{mL}$. In DMBA cancer cells-induced rats, compound 95 hindered the breast-histological and carcinogenic lesions when treated for ten weeks. It is also reported that polysaccharides extracted from this seaweed have possible chemopreventive properties against mammary carcinogenesis by increasing apoptosis, reducing oxidative stress, and enhancing the antioxidant defense system [56]. Fucoidan 96 represents a sulfated polysaccharide isolated from different marine brown seaweeds such as *Saccharina japonica*. At 200 mg/mL, this material showed antitumor activity against T-47D with 46% proliferation inhibition after 48 h [57]. Native carrageenan (κ) (97) was isolated from the red seaweed *Kappaphycus alvarezii*. Compound 97 showed activity against cell viability in a dose-dependent manner in breast adenocarcinoma MCF-7 cell lines, displaying an IC_{50} value of 123.8 $\mu\text{g}/\text{mL}$ [58].

3.2. Sesquiterpenes and monoterpenes

The guai-2-en-10 α -ol (98) (Fig. 14) is a guaiane sesquiterpenoid,

reported from the marine green seaweed *Ulva fasciata*. Compound 98 revealed growth inhibition in the triple-negative breast cancer (TNBC) MDA-MB-231 cancer cell line with IC_{50} values of 17.35 ± 1.23 (after 12 h) and $12.98 \pm 1.11 \mu\text{M}$ (after 24 h), respectively. Compound 98 hindered the cell cycle in the G1 phase of the MDA MB-231 cancer cell line, leading to apoptosis. The downregulation of both PI3K and EGFR proteins was observed and this suggesting its anticancer potential *via* the EGFR/PI3K/Akt pathway [59].

Two eudesmane sesquiterpenes named eudesma-4(15),7-diene-5,11-diol (99) and chabrolidione B (101), along with trinor-sesquiterpene, teuhetenone (100) were produced by the red alga *Laurencia obtuse*. Compounds 99–101 displayed cytotoxic effects towards MCF-7 with IC_{50} : of 39.5, 22.8, and 63.6 μM , respectively. Notably, teuhetenone (100) displayed a higher activity than cisplatin (IC_{50} : 59 μM) [60]. RU015 (102) and RU008 (103) represent polyhalogenated monoterpenes isolated from the marine red algae *Plocamium* sp. Compound 102 showed potential cytotoxicity against three breast cancer cells including MDA-MB-231, MCF-7 and MCF12A with IC_{50} : 6.2, 3.6 and 3.5 μM , respectively. Similarly, compound 103 illustrated cytotoxicity towards the MDA-MB-231 with an IC_{50} : 82.7 μM [61].

3.3. Meroterpenoids and diterpenes

Laurenditerpenol (104) (Fig. 15), a diterpene isolated from the lipid extract of the marine red alga *Laurencia intricate*, was shown to inhibit Hypoxia-Inducible Factor-1 (HIF-1). This latter is a heterodimer constituted of two subunits: HIF-1 α , which is regulated by cellular oxygen levels, and HIF-1 β that is constitutively expressed and identified as a valuable molecular target for anticancer drug discovery. More precisely, compound 104 inhibited HIF-1 activation in T-47D cell line with an IC_{50} : 0.4 μM [62]. Sargaquinic acid (SQA, 105) and

Table 2
Compounds 95–119 with cytotoxic effects.

| Name | Organism | Cell line | Cytotoxicity | Ref. |
|---|---------------------------------|------------|---|------|
| Polysaccharide (95) | <i>Ulva lactuca</i> | MCF-7 | IC ₅₀ : 224.716 µg/mL Inhibition: 46% | [56] |
| Fucoidan (96) | <i>Saccharina japonica</i> | T-47D | IC ₅₀ : 123.8 µg/mL | [57] |
| Carrageenan (κ) (97) | <i>Kappaphycus alvarezii</i> | MCF-7 | IC ₅₀ : 12.98 µM | [58] |
| Guai-2-en-10α-ol (98) | <i>Ulva fasciata</i> | MDA-MB-231 | IC ₅₀ : 39.5 µM | [59] |
| Eudesma-4(15),7-diene-5,11-diol (99) | <i>Laurencia obtuse</i> | MCF-7 | IC ₅₀ : 12.98 µM | [60] |
| Teuhetenone (100) | <i>Laurencia obtuse</i> | MCF-7 | IC ₅₀ : 22.8 µM | [60] |
| chabrolidione B (101) | <i>Laurencia obtuse</i> | MCF-7 | IC ₅₀ : 63.6 µM | [60] |
| RU015 (102) | <i>Plocamium sp.</i> | MDA-MB-231 | IC ₅₀ : 6.2 µM | [61] |
| | | MCF-7 | IC ₅₀ : 3.6 µM | [61] |
| | | MCF12A | IC ₅₀ : 3.5 µM | [61] |
| RU008 (103) | <i>Plocamium sp.</i> | MDA-MB-231 | IC ₅₀ : 82.7 µM | [61] |
| Laurenditerpenol (104) | <i>Laurencia intricata</i> | T-47D | IC ₅₀ : 0.4 µM | [62] |
| Sargaquinoic acid (SQA) (105) | <i>Sargassum heterophyllum</i> | MBA-MB-231 | IC ₅₀ : 67.4 µM | [61] |
| Sargahydroquinoic acid (SHQA) (106) | <i>Sargassum heterophyllum</i> | MBA-MB-231 | IC ₅₀ : 159.5 µM | [61] |
| tetraprenyltoluquinol derivatives (107–111) | <i>Cystoseira crinita</i> | MCF-7 | GI ₅₀ : 0.9–2.5 µg/mL | [63] |
| Galaxamide (112) | <i>Galaxaura filamentosa</i> | MCF-7 | IC ₅₀ : 14.0 µg/mL | [64] |
| Fucoxanthin (FXN) (113) | <i>Sargassum heterophyllum</i> | MBA-MB-231 | IC ₅₀ : 109.4 µM | [61] |
| Dehydrothyrisferol (114) | <i>Sargassum heterophyllum</i> | T-47D | IC ₅₀ : 7.09 µM | [65] |
| | | MBA-MB-231 | IC ₅₀ : 14.8 µM | [65] |
| Violaxanthin (115) | <i>Dunaliella tertiolecta</i> | MCF-7 | GI ₅₀ : 56.1 µg/mL | [66] |
| Curacin A (116) | <i>Lyngbya majuscule</i> | MCF-7 | GI ₅₀ : 0.038 µM | [69] |
| 2,4-Diacetylphloroglucinol (DAPG) (117) | <i>Ceratodictyon spongiosum</i> | MDA-MB-231 | IC ₅₀ : 0.08 µM | [70] |
| Phloroglucinol (118) | marine brown algae | MDA-MB231 | IC ₅₀ : 50 µM | [71] |
| Dioxinodehydroeckol (119) | <i>Ecklonia cava</i> | MCF-7 | Inhibition: 64% | [72] |

sargahydroquinoic acid (SHQA, 106) (Fig. 16) are produced by the marine algae *Sargassum heterophyllum* and illustrated cytotoxicity towards MBA-MB-231 with IC₅₀: 67.4, and 159.5 µM, respectively [61]. Meroterpenoids, tetraprenyltoluquinol derivatives 107–111 produced by the brown algae *Cystoseira crinita* illustrated significant cytotoxicity towards MCF-7 with GI₅₀ values ranging from 0.9 and 2.5 µg/mL, respectively. Notably, compounds 109 and 110 bearing the furan ring possessed better effects with GI₅₀: 1.3 and 0.9 µg/mL, respectively [63].

3.4. Micellaneous

Galaxamide (112), a cyclic pentapeptide produced by *Galaxaura filamentosa*, was shown to possess three leucines and two N-methyl leucine moieties. It exhibited cytotoxic effects towards MCF-7 cell lines with an IC₅₀: 14.0 µg/mL [64]. Fucoxanthin (FXN, 113) (Fig. 16) is produced by the marine algae *Sargassum heterophyllum* and illustrated cytotoxicity towards MBA-MB-231 with IC₅₀: 109.4 µM [61]. Dehydrothyrisferol (114) is an anti-toxin terpenoid isolated from the marine algae *Laurencin viridis*. Compound 114 exhibited cytotoxicity against T-47D and MBA-MB-231 with IC₅₀: 7.09 and 14.8 µM, respectively [65]. *Dunaliella tertiolecta* (DT), a green microalgae, produced violaxanthin (115) as the major antiproliferative pigment and induced MCF-7 growth inhibition [66].

Curacin A (116), containing a thiazoline moiety, cyclopropane group, and cis-alkenyl group, terminal double bond alkaloid that was discovered by Gerwick and his coworkers from the marine cyanobacterium *Lyngbya majuscule* [67] found in Curaçao. Its absolute configuration was established some years later by comparing degradative fragments with materials produced by enantioselective synthesis [68]. Compound 116 revealed anti-proliferative effects against the MCF-7 human cancer cell line with a GI₅₀ value of 0.038 µM. It showed to block cell cycle progression by inhibiting the tubulin polymerization due to its high affinity to the colchicine-binding site on tubulin [69].

2,4-Diacetylphloroglucinol (DAPG) (117) (Fig. 18) is a polyketide reported from *Pseudomonas* sp. isolated from the surface of marine red alga *Ceratodictyon spongiosum*. Compound 117 inhibited the proliferation of MDA-MB-231 with IC₅₀: 0.08 µM [70] (Table 2). Phloroglucinol (118) is a phlorotannin isolated from marine brown algae and it significantly suppressed the invasive and migratory ability of the cell line MDA-MB231 in a dose-dependent manner [71]. Dioxinodehydroeckol (119), a phloroglucinol derivative, was reported from the edible marine brown alga *Ecklonia cava*. At a concentration at 100 µM, this compound induced apoptosis in MCF-7 cells at the rate of 64%. Further investigations suggested that apoptosis in MCF-7 cells may be modulated through the NF-κappaB family and NF-κappaB dependent pathway [72] (Fig. 17).

4. Marine bacteria

4.1. Peptides

Cocosamides A (120) and B (121) along with malyngamide 3 (122) were isolated from *Moorea producens* (formerly *Lyngbya majuscule*) (Fig. 18). Compounds 120–122 demonstrated cytotoxicity towards MCF-7 with IC₅₀: 30, 39, and 29 µM, respectively [73]. Wewakazole B (123) is a cytotoxic peptide isolated from the red sea cyanobacteria *Moorea producens*. Compound 123 has shown potent cytotoxicity towards the MCF-7 human mammary cancer cell line with an IC₅₀ value of 0.58 µM [74]. Hantupeptins A–C (124–126) are cyclodepsipeptides produced by cyanobacterium *Lyngbya majuscule* [75]. Compounds 124–126 displayed cytotoxicity against MCF-7 with IC₅₀: 4.0, 0.5, and 1.0 µM, respectively [76].




Fig. 17. Structures of miscellaneous compounds 117–119.




Fig. 19. Structures of peptides 127–139.

Kailuins A–D (127–130) (Fig. 19) are cyclic acyldepsipeptides isolated from a liquid culture of the gram-negative bacterium *BH-107*, collected from the beach of Kailua. Compounds 127–130 demonstrated cytotoxicity against MCF-7 with GI₅₀: 3, 2, 4, and 3 µg/mL, respectively [77]. Laxaphycins B (131) is a cytotoxic cyclopeptide obtained from the marine cyanobacteria *Lyngbya majuscula* and it showed inhibition of the MCF-7 proliferation with IC₅₀: 0.5 µM [78]. Pitiprolamide (132) is a cyclic depsipeptide and obtained from the cyanobacterium *Lyngbya majuscula*. Compound 132 showed mild inhibitory effects towards the MCF-7 breast cancer cell line with an IC₅₀ value of 33.0 µM [79]. Pitipeptolides A–C (133–135), and F (136) are cyclic depsipeptides obtained from the marine cyanobacterium *Lyngbya majuscula* from the Piti Bomb holes of Guam [80,81]. Compounds 133–136 showed cytotoxicity

towards the MCF-7 cell line with IC₅₀: 13, 11, 73, and 83 µM, respectively [81].

Symplostatin 1 (137) is a linear peptide that corresponds to the dolastatin 132. It was taken off from the marine cyanobacteria *Symploca hydnoidea*. Compound 137 was shown to inhibit cell propagation of MDA-MB-435 very efficiently, displaying an IC₅₀ value of 0.15 nM [82]. Bacillistatins 1 (138) and 2 (139) are 12-unit cyclic cyclodepsipeptides, taken from cultures of *Bacillus silvestris*, obtained from the Pacific Ocean. Bacillistatin 1 (138) possesses a 2R-hydroxy-3S-methylvaleric acid. On the other hand, bacillistatin 2 (139) possesses the isomeric 2R-hydroxy-4-methylvaleric acid moiety residue. The relative stereochemistry of bacillistatin 1 is confirmed by X-ray crystallographic techniques. Compounds 138 and 139 showed potent cytotoxic activity towards MCF-7




Fig. 20. Structures of peptides 140–145.

owing GI₅₀ values of 0.00027 and 0.00053 µg/mL, respectively [83].

Coibamide A (**140**) (Fig. 20) is a depsipeptide with antiproliferative properties isolated from the filamentous marine cyanobacterium *Lep-tolyngbya* sp. This compound was tested against a 60 cell line panel of the NCI (National Cancer Institute) and showed the highest effectiveness to the MDA-MB-231 human breast tumor cell line with a GI₅₀ value of 2.8 nM [84]. Largazole (**141**) is a cyclodespeptide taken from a floridian marine cyanobacterium *Symploca* sp. At high concentration, compound **141** strongly prevented the growth of invasive transformed (MDA-MB-231) human mammary epithelial cells in a well regular manner (GI₅₀ 7.7 nM and LC₅₀ 117 nM). On the other hand, murine mammary epithelial cells that are nontransformed (NMuMG) were less sensitive to compound **141** (GI₅₀ 122 nM, and LC₅₀ 272 nM) [85].

Somocystinamide A (**142**) is a marine lipopeptide isolated from a cyanobacteria *L. majuscula/Schizothrix*. This disulfide dimer of mixed PKS/NRPS biosynthetic origin is responsible for apoptosis via the lipid partition, leading to accumulating the ceramide in treated cells. After that, it follows the colocalization pathway with caspase 8. Compound **142** efficiently showed inhibition of the MCF- 7 cell line with an IC₅₀ value of 210 nM [86]. Belamide A (**143**) isolated from the marine cyanobacterium *Symploca* sp. Pure belamide A (**143**) possessed cytotoxic effects towards MCF-7 cell line with an IC₅₀: 1.6 μ M [87]. Two depsipeptides, neoantimycins D (**144**) and E (**145**) were isolated from

Streptomyces sp. and both compounds possessed cytotoxicity towards MCF-7 with an inhibition rate of 91% and 90.5% respectively [88].

4.2. Alkaloids

ZHD-0501, dimeric indole alkaloid (**146**) (Fig. 21) is a staurosporine derivative reported from the marine actinomycete *Actinomadura sp.* 007. This compound showed the ability to reduce the proliferation of the temperature-sensitive FT210 (*tsFT210*) mouse breast cancer cell line [89]. Streptokordin (**147**) is a methyl pyridine alkaloid isolated from the *Streptomyces* sp. KORDI-3238, which illustrated cytotoxicity towards MDA-MB-231 with an IC₅₀ value of 7.5 µg/mL [90]. Diazepinomicin (**148**) is a dibenzodiazepine alkaloid, obtained from cultures of the marine actinomycete strain *Micromonospora DPJ12*. This compound showed a cytotoxic effect towards the MDA-MB-231 with IC₅₀: 2.1 µM [91] (Table 3).

Caboxamycin (**149**) and UK-1 (**150**) are benzoxazole compounds that were reported from the marine *Streptomyces* species NTK 937, isolated from deep-sea marine sediments in the Canary Basin. Compounds **149** and **150** displayed a growth efficient inhibitory activity against MCF-7 with a GI₅₀: of 7.3 and 0.65 μ M, respectively [92]. Pseudonocardian C (**151**) was isolated from the marine actinomycete *Pseudonocardia* sp. and showed efficient cytotoxic effects towards MCF-7 with




Fig. 21. Structures of alkaloids 146–151.

IC_{50} : 8.0 μM [93].

Pyridinium 152 (Fig. 22) was isolated and identified from the actinomycete *Amycolatopsis alba* var. nov. DVR D4 strain. It was obtained from sea sediments from the Visakhapatnam coast of the Bengal Bay, India. This compound revealed cytotoxic activity against MCF-7 with percentage inhibition of 60.4% [94]. Iodinin (153), 1,6-phenazinediol (154), questiomycin (155), chandrananimycins A-C (156–158) and phenoxazin-3-one (159) were obtained from *Actinomadura* sp. M048 isolates from marine sediments collected at Jiaozhou Bay, China. Both compounds 153 and 154 showed antitumor activity against breast cancer MAXF 401NL cells with IC_{50} < 4.0 $\mu\text{g}/\text{mL}$. On the other hand compounds 155–159 were found to be active against MCF-7 with IC_{50} values down to 1.4 $\mu\text{g}/\text{mL}$ [95].

Aminophenoxazinones 160–162 (Fig. 23) were isolated from *Halomonas* sp. and exhibited cytotoxic effects towards MCF-7, having GI_{50} values of 0.13, 1.6, and 2.0 $\mu\text{g}/\text{mL}$, respectively [96]. Aqabamycin E (163) and vibrindole A (164) were isolated from certain bacteria *Vibrio* species and showed moderate cytotoxicity towards MDA-MB-231 and MCF-7 cell lines with IC_{50} values of 25 and 20 $\mu\text{g}/\text{mL}$ and 30 and 50 $\mu\text{g}/\text{mL}$, respectively [97].

4.3. Quinones

Isoquinolinequinones, mansouramycins A-C (165–167) along with 3-methyl-7-(methylamino)- 5,8-isoquinolinedione (168) (Fig. 24) were obtained from cultures of the *Streptomyces* sp. Compounds 165–168 possess cytotoxic effects towards MCF-7 and 401NL with an IC_{50} : ranging from 0.012 to 47.7 μM . Notably compounds 165, 167, & 168 were significantly more active towards MCF-7 with IC_{50} : 2.3, 0.012 and 1.1 μM , respectively [98]. Pseudonocardians A (169) and B (170) were isolated from the marine actinomycete *Pseudonocardia* sp. strain SCSIO 02199 collected from deep-sea sediments off the South China Sea. Compounds 169 and 170 showed efficient cytotoxic effects towards MCF-7 with IC_{50} values of 0.027, and 0.021 μM , respectively [93].

Parimycin (2,3-dihydro-1, 4-anthraquinone) (171) was isolated from cultures of the marine *Streptomyces* sp. strain B8652 and possess good

effects towards MCF-7 [99]. Marmycins A (172) and B (173) are anthraquinones of the angucycline class produced by the *Streptomyces* strain CNH990. Compound 172 showed cytotoxicity towards breast cancer displaying IC_{50} : < 0.03 μM while marmycin B (173) proved to be less potent than 172 (IC_{50} : < 0.5 μM) [100].

Grincamycins B-F (174–178) and grincamycin (179) (Fig. 25) are classified as the C-glycoside angucycline-type metabolites. Compounds 174–179 were obtained from the fermentation of the marine actinobacteria *Streptomyces lusitanus* SCSIO LR32, collected in the South China Sea. All the compounds (174–179) demonstrated cytotoxicity towards MCF-7 with IC_{50} values of 12, 11, 6.1, 8.7, 19, and 2.1 μM , respectively [101]. Chinikomycin B (180) was also isolated from the *Streptomyces* sp. and showed good antitumor activity towards MAXF 401NL with IC_{50} : 3.04 $\mu\text{g}/\text{mL}$ [102]. Kosinostatin (181) is a cytotoxic compound, reported from the *Micromonopora* strain TP-A0468, which showed efficient cytotoxicity in HBC-5, MCF-7, HBC-4, BSY-1, and MDA-MB-231 breast cancer cells with IC_{50} values of 0.10, 0.05, 0.02, 0.06, and 0.21 μM , respectively [103]. 2-hydroxyethyl-3-methyl-1,4-naphthoquinone 182 was isolated from *Actinoalloteichus cyanogriseus* and possessed cytotoxic effect towards MDA-MB-435 with IC_{50} 10.5 μM [104].

4.4. Miscellaneous

Chinikomycin A (183) (Fig. 26) was isolated from the *Streptomyces* sp. and showed good antitumor activity towards MAXF 401NL with IC_{50} : 2.41 $\mu\text{g}/\text{mL}$ [102]. Arisostatin A (184) is an antibiotic belonging to the tetrocarcin class and was isolated from cultures of *Micromonospora* sp. This compound, 184, displayed cytotoxic activity against HBC-4 and HBC-5 with IC_{50} : 0.26 and 0.059, μM , respectively [105]. Chromomycins A₅A₈ (185–188) were isolated from the marine bacteria, *Streptomyces* sp., collected from marine Zoanthid *Palythoa caribaeorum*. Compounds 185–188 reduced the viability of human MCF-7 tumor cells with IC_{50} values of 3.7, 14.7, 133.0, and 10.5 nM, respectively [106]. Desertomycin G (189) is a member of the amino polyol polyketides containing a macrolactone ring produced by the marine-derived cyanobacteria *Streptomyces althioticus* MSM3 on the surface of the marine

Table 3
Compounds 120–210 having anti-breast cancer properties.

| Name | Organism | Cell line | Cytotoxicity | Ref. |
|--------------------------|----------------------------------|------------------|----------------------------------|----------|
| Cocosamide A (120) | <i>Moorea producens</i> | MCF-7 | IC ₅₀ : 30 μM | [73] |
| Cocosamide B (121) | <i>Moorea producens</i> | MCF-7 | IC ₅₀ : 39 μM | [73] |
| Malyngamide 3 (122) | <i>Moorea producens</i> | MCF-7 | IC ₅₀ : 29 μM | [73] |
| Wewakazole B (123) | <i>Moorea producens</i> | MCF-7 | IC ₅₀ : 0.58 μM | [74] |
| Hantupeptin A (124) | <i>Moorea producens</i> | MCF-7 | IC ₅₀ : 4.0 μM | [75, 76] |
| Hantupeptin B (125) | <i>Moorea producens</i> | MCF-7 | IC ₅₀ : 0.5 μM | [75, 76] |
| Hantupeptins A–C (126) | <i>Moorea producens</i> | MCF-7 | IC ₅₀ : 1.0 μM | [75, 76] |
| Kailuin A (127) | <i>BH-107</i> | MCF-7 | GI ₅₀ : 3 μg/mL | [77] |
| Kailuin B (128) | <i>BH-107</i> | MCF-7 | GI ₅₀ : 2 μg/mL | [77] |
| Kailuin C (129) | <i>BH-107</i> | MCF-7 | GI ₅₀ : 4 μg/mL | [77] |
| Kailuin D (130) | <i>BH-107</i> | MCF-7 | GI ₅₀ : 3 μg/mL | [77] |
| Laxaphycins B (131) | <i>Lyngbya majuscula</i> | MCF-7 | IC ₅₀ : 0.5 μM | [78] |
| Pitiprolamide (132) | <i>Lyngbya majuscula</i> | MCF-7 | IC ₅₀ : 33.0 μM | [79] |
| Pitipeptolide A (133) | <i>Lyngbya majuscula</i> | MCF-7 | IC ₅₀ : 13 μM | [80, 81] |
| Pitipeptolide B (134) | <i>Lyngbya majuscula</i> | MCF-7 | IC ₅₀ : 11 μM | [80, 81] |
| Pitipeptolide C (135) | <i>Lyngbya majuscula</i> | MCF-7 | IC ₅₀ : 73 μM | [80, 81] |
| Pitipeptolides F (136) | <i>Lyngbya majuscula</i> | MCF-7 | IC ₅₀ : 83 μM | [80, 81] |
| Symplostatin 1 (137) | <i>Symploca hydnoides</i> | MDA-MB-435 | IC ₅₀ : 0.15 nM | [82] |
| Bacillistatin 1 (138) | <i>Bacillus silvestris</i> | MCF-7 | GI ₅₀ : 0.00027 μg/mL | [83] |
| Bacillistatin 2 (139) | <i>Bacillus silvestris</i> | MCF-7 | GI ₅₀ : 0.00053 μg/mL | [83] |
| Coibamide A (140) | <i>Leptolyngbya</i> sp. | MDA-MB-231 | GI ₅₀ : 2.8 nM | [84] |
| Largazole (141) | <i>Symploca</i> sp. | MDA-MB-231 | GI ₅₀ : 7.7 nM | [85] |
| Somocystinamide A (142) | <i>L. majuscula/ Schizothrix</i> | MCF-7 | IC ₅₀ : 210 nM | [86] |
| Belamide A (143) | <i>Symploca</i> sp. | MCF-7 | IC ₅₀ : 1.6 μM | [87] |
| Neoantimycins D (144) | <i>Streptomyces</i> sp. | MCF-7 | Inhibition rate: 91% | [88] |
| Neoantimycins E (145) | <i>Streptomyces</i> sp. | MCF-7 | Inhibition rate: 90.5% | [88] |
| ZHD-0501 (146) | <i>Actinomadura</i> sp. 007 | tsFT210 | Inhibition rate: 28.3% | [89] |
| Streptokordin (147) | <i>Streptomyces</i> sp. | MDA-MB-231 | IC ₅₀ : 7.5 μg/mL | [90] |
| Diazepinomicin (148) | <i>Micromonospora DPJ12</i> | MDA-MB-231 | IC ₅₀ : 2.1 μM | [91] |
| Caboxamycin (149) | <i>Streptomyces</i> species | MCF-7 | GI ₅₀ : 7.3 μM | [92] |
| UK-1 (150) | <i>Streptomyces</i> species | MCF-7 | GI ₅₀ : 0.65 μM | [92] |
| Pseudonocardian C (151) | <i>Pseudonocardia</i> sp. | MCF-7 | IC ₅₀ : 8.0 μM | [93] |
| Pyridinium (152) | <i>Amycolatopsis alba</i> | MCF-7 | Inhibition: 60.4% | [94] |
| Iodinin (153) | <i>Actinomadura</i> sp. M048 | MAXF 401NL cells | IC ₅₀ : < 4.0 μg/mL | [95] |
| 1,6-phenazinediol (154) | <i>Actinomadura</i> sp. M048 | MAXF 401NL cells | IC ₅₀ : < 4.0 μg/mL | [95] |
| Questiomycin (155) | <i>Actinomadura</i> sp. M048 | MCF-7 | IC ₅₀ : < 1.4 μg/mL | [95] |
| Chandrananimycin A (156) | <i>Actinomadura</i> sp. M048 | MCF-7 | IC ₅₀ : < 1.4 μg/mL | [95] |

Table 3 (continued)

| Name | Organism | Cell line | Cytotoxicity | Ref. |
|--------------------------|------------------------------|-----------------------|--|----------------|
| Chandrananimycin B (157) | <i>Actinomadura</i> sp. M048 | MCF-7 | IC ₅₀ : < 1.4 μg/mL | [95] |
| Chandrananimycin C (158) | <i>Actinomadura</i> sp. M048 | MCF-7 | IC ₅₀ : < 1.4 μg/mL | [95] |
| Phenoxyazin-3-one (159) | <i>Actinomadura</i> sp. M048 | MCF-7 | IC ₅₀ : < 1.4 μg/mL | [95] |
| Aminophenoxyazinone 160 | <i>Halomonas</i> sp. | MCF-7 | GI ₅₀ : 0.13 μg/mL | [96] |
| Aminophenoxyazinone 161 | <i>Halomonas</i> sp. | MCF-7 | GI ₅₀ : 1.6 μg/mL | [96] |
| Aminophenoxyazinones 162 | <i>Halomonas</i> sp. | MCF-7 | GI ₅₀ : 2.0 μg/mL | [96] |
| Aqabamycin E (163) | <i>Vibrio</i> species | MDA-MB-231 | | |
| | MCF-7 | | IC ₅₀ : 25 μg/mL | |
| | Vibrindole A (164) | <i>Vibrio</i> species | MDA-MB-231 | |
| | | | IC ₅₀ : 20 μg/mL | |
| | | | IC ₅₀ : 50 μg/mL | [97] |
| | | | Streptomyces | MCF-7 |
| | | | IC ₅₀ : 2.3 μM | [98] |
| | | | Mansouramycins A (165) | Streptomyces |
| | | | Mansouramycins B (166) | Streptomyces |
| | | | Mansouramycins C (167) | Streptomyces |
| | | | 3-Methyl-7-(methylamino)-5,8-isoquinolinedione (168) | Streptomyces |
| | | | Pseudonocardian A (169) | Pseudonocardia |
| | | | Pseudonocardian B (170) | Pseudonocardia |
| | | | Parimycin (2, 3-dihydro-1, 4-anthraquinone) (171) | |
| | | | Marmycins A (172) | Streptomyces |
| | | | Marmycins B (173) | Streptomyces |
| | | | Grincamycins B (174) | Streptomyces |
| | | | Grincamycins C (175) | Streptomyces |
| | | | Grincamycins D (176) | Streptomyces |
| | | | Grincamycins E (177) | Streptomyces |
| | | | Grincamycins F (178) | Streptomyces |
| | | | Grincamycins G (179) | Streptomyces |
| | | | Chinikomycin B (180) | Streptomyces |
| | | | Kosinostatin (181) | |
| | | | Micromonopora strain TP-A0468 | |
| | | | MAXF 401NL | |
| | | | HBC-5; | |
| | | | MCF-7; | |
| | | | HBC-4; | |
| | | | BSY-1; | |
| | | | MDA-MB-231 | |
| | | | IC ₅₀ : | |
| | | | 0.06 μM; | |
| | | | IC ₅₀ : 0.21 μM | |
| | | | IC ₅₀ : 10.5 μM | [104] |
| | | | Arisostatin A (184) | |
| | | | (continued on next page) | [105] |

Table 3 (continued)

| Name | Organism | Cell line | Cytotoxicity | Ref. |
|-----------------------------------|---|-----------------|--------------------------------------|-------|
| Chromomycins A ₅ (185) | <i>Streptomyces</i> sp. | HBC-4 and HBC-5 | IC ₅₀ : 0.26 and 0.059 μM | |
| | | MCF-7 | IC ₅₀ : 3.7 μM | [106] |
| Chromomycins A ₆ (186) | <i>Streptomyces</i> sp. | MCF-7 | IC ₅₀ : 14.7 μM | [106] |
| Chromomycins A ₇ (187) | <i>Streptomyces</i> sp. | MCF-7 | IC ₅₀ : 133.0 μM | [106] |
| Chromomycins A ₈ (188) | <i>Streptomyces</i> sp. | MCF-7 | IC ₅₀ : 10.5 μM | [106] |
| Desertomycin G (189) | <i>Streptomyces althioticus</i> | MCF-7 | IC ₅₀ : 3.8 μM | [107] |
| Tartrolon D (190) | <i>Streptomyces</i> sp. | MDA-MB-231 | GI ₅₀ : 0.79 μM | [108] |
| 7-Deoxyechinosporin (191) | <i>Streptomyces albogriseolus</i> A2002 | MCF-7 | GI ₅₀ : 0.4 μM | [109] |
| Echinosporin (192) | <i>Streptomyces albogriseolus</i> | MCF-7 | GI ₅₀ : 6.4 μM | [109] |
| Trioxacarcins A (193) | <i>Streptomyces</i> sp. strain B8652 | MCF-7 | IC ₅₀ : < 0.0003 μg/mL | [110] |
| Trioxacarcins B (194) | <i>Streptomyces</i> sp. strain B8652 | MCF-7 | IC ₅₀ : 1.134 μg/mL | [110] |
| Trioxacarcins C (195) | <i>Streptomyces</i> sp. | MCF-7 | IC ₅₀ : 0.002 μg/mL | [110] |
| Trioxacarcins D (196) | <i>Streptomyces</i> sp. | MCF-7 | IC ₅₀ : 0.066 μg/mL | [110] |
| Proximicins A (197) | <i>Verrucospora</i> | MCF-7 | GC ₅₀ : 24.6 μM | [111] |
| Proximicins B (198) | <i>Verrucospora</i> | MCF-7 | GC ₅₀ : 12.1 μM | [111] |
| Proximicins C (199) | <i>Verrucospora</i> | MCF-7 | GC ₅₀ : 20.6 μM | [111] |
| PM100117 (200) | <i>Streptomyces caniferus</i> | MDA-MB-231 | GI ₅₀ : 1.5 μM | [112] |
| PM100118 (201) | <i>Streptomyces caniferus</i> | MDA-MB-231 | GI ₅₀ : 1.7 μM | [112] |
| Streptomyceamide C (202) | <i>Streptomyces</i> sp. H74-21 | MCF-7 | IC ₅₀ : 27.0 μg/mL | [113] |
| Chromophore-V C-1027 (203) | <i>Streptomyces</i> sp. strain MB231 | MDA-MB-231 | IC ₅₀ : 0.9 μM | [114] |
| ULDF4 (204) | <i>Streptomyces</i> sp. | MCF-7 | IC ₅₀ : 0.0139 mg/mL | [115] |
| ULDF5 (205) | <i>Streptomyces</i> sp. | MCF-7 | IC ₅₀ : 2.176 mg/mL | [115] |
| Sesbanimide A (206) | <i>Stappia indica</i> | MDA-MB-23 | GI ₅₀ : 6.4E-07 | [116] |
| Sesbanimides C-F (207-210) | <i>Labrenzia aggregata</i> | MDA-MB-23 | GI ₅₀ : 1.6E-07-8.6E-09 | [116] |

algal (*Ulva* sp.) colony which was collected from the sediment of the North Atlantic Ocean. This compound, **189**, showed a powerful reduction in the feasibility of MCF-7 cells displaying an IC₅₀: 3.8 μM after 96 h [107].

Tartrolon D (**190**) (Fig. 27) is a macrodiolide isolated from marine sediments of the actinomycete *Streptomyces* sp. This compound showed potent cytotoxicity towards MDA-MB-231 with GI₅₀: 0.79 μM [108]. 7-Deoxyechinosporin (**191**) and echinosporin (**192**) are lactones that were extracted from the microbes *Streptomyces albogriseolus* A2002 collected from sea sediment in Jiaozhou Bay, China. Compounds **191** and **192** indicated antiproliferative properties towards MCF-7 with GI₅₀: 0.4 and 6.4 μM, respectively [109]. Trioxacarcins A-D (**193-196**) were obtained from marine *Streptomyces* sp. strain B8652 and exhibited excellent cytotoxicity towards MCF-7 with IC₅₀: < 0.0003, 1.134, 0.002, and 0.066 μg/mL, respectively [110].

Proximicins A-C (**197-199**) (Fig. 28) are three furan derivatives of netropsin, isolated from the actinomycete *Verrucospora*. These compounds differ from the previously reported heterocyclic antibiotics, such as netropsin and distamycin, by the presence of the γ-amino acid 4-aminofuran-2-carboxylic acid group. Compounds **197-199** have efficient cytotoxic effects against the human MCF-7 mammary tumor cell lines showing GI₅₀ values of 24.6, 12.1, and 20.6 μM, respectively. Preliminary investigations on their mechanism of action suggested that proximicins arrest cells in the G₀/G₁ phase [111].

PM100117 (**200**) and PM100118 (**201**) (Fig. 29) are the polyhydroxy macrolide lactones discovered from the broth cultures of the marine-derived *Streptomyces caniferus* which was obtained from the Guadeloupe Island in the Pacific Ocean. Their skeleton comprises of a 36-membered macrolide, possessing a side chain with 3 deoxy sugars and an important 1, 4-naphthoquinone chromophore. Both compounds **200** and **201** have efficient antitumor effects on MDA-MB-231 with GI₅₀: 1.5 and 1.7 μM, respectively [112]. Streptomyceamide C (**202**) was isolated from the *Streptomyces* sp. H74-21 isolate which in turn was derived from marine sediments present in tropical mangrove sites. Compound **202** showed anti-proliferative effects towards MCF-7 with an IC₅₀ value of 27.0 μg/mL [113].

Chromophore-V C-1027 (**203**) belongs to the family of benzoxazine metabolites isolated from the Arctic marine actinomycete *Streptomyces* strain and showed significant cytotoxicity against MDA-MB231 cells exhibiting an IC₅₀ value of 0.9 μM [114]. ULDF4 (**204**) and ULDF5 (**205**) resemble the chemical class of polycyclic xanthones, were isolated from 12 diverse deposit collections of marine-derived actinomycete named as *Streptomyces bingchengensis* ULS14. Compounds **204** and **205** showed cytotoxicity against human MCF-7 mammary adenocarcinoma cells with IC₅₀ values of 0.0139 and 2.176 mg/mL, respectively [115]. Polyketides named sesbanimide A (**206**), and sesbanimides C-F (**207-210**) were produced bacteria *Stappia indica* and *Labrenzia aggregata*. Moreover




Fig. 22. Structures of alkaloids 152-159.




Fig. 23. Structures of alkaloids 160–164.




Fig. 24. Structures of quinones 165–173.

these metabolites demonstrated cytotoxic effects towards MDA-MB-231 with GI_{50} : 1.6E-07–8. 6E-09 [116].

5. Marine fungi

5.1. Sesquiterpenes and sesterterpenes

Coriolin B (211) (Fig. 30) is a cyclic chlorinated sesquiterpene obtained from the marine sponge known as *Jaspis aff. Johnstonei*. This compound demonstrated cytotoxicity towards the T-47D cell lines with an IC_{50} value of $0.7 \mu\text{M}$ [117]. Neomangicols A (212) and B (213) are sesterterpenes isolated from the derived marine fungal strain *Fusarium equiseti* CNC-477 collected from the mangroves in the Bahamas. Compounds 212 and 213 showed cytotoxicity towards MCF-7 with IC_{50} : 4.9 and $27 \mu\text{M}$, respectively [118]. Ophiobolin O (214) is a sesterterpene that was derived from the *Aspergillus ustus* fungal strain 094102, isolated from the Mediterranean sponge *Suberites domuncula*. Ophiobolin O showed IC_{50} values of $17.8 \mu\text{M}$ towards MCF-7 cells and to arrest cell cycle progression in the G₁ phase, through interaction with AKT/GSK3β/cyclin D1 signaling pathway [119]. The sesquiterpenoid nitrobenzoyl ester derivative, 9α,14-dihydroxy-6β-p-nitrobenzoylcinnamolide (215) was identified from the algicolous fungus mycelia *Aspergillus versicolor* CNC 327 found on the external surface of the green calcareous alga *Penicillium capitatum* from the Bahamas Islands.

This compound showed inhibitory activity against the BT-549 line, an invasive ductal tumor, with an LC_{50} value of $0.27 \mu\text{g/mL}$ [120].

5.2. Alkaloids

Avrainvillamide (216) (Fig. 31) was produced by *Aspergillus* sp. CNC358 isolate, in turn isolated from the green alga *Avrainvillea* sp. collected from an island of the Bahamas. Compound 216 exhibited inhibitory activity towards βT-549 and T-47D with IC_{50} values of 34 and 72 nM, respectively [121]. Acetylapoaranotin (217), acetylaranotin (218), and deoxyapoaranotin (219) were isolated from a derived-marine fungus *Aspergillus* sp. and illustrated cytotoxicity towards MCF-7 with IC_{50} values of 10, 36, and 31 μM , respectively [122]. Gliotoxin (220), another member of the sulfur-containing diketopiperazine class, was isolated from the sea-derived fungus *Aspergillus* sp. strain YL-06. Compound 220 illustrated potent cytotoxicity towards MCF-7, T47D, BT-474, ZR75-1, MDA-MB231, and MDA-MB435, with IC_{50} value of 985, 365, 102, 158, 138, and 87, respectively [123] (Table 4).

Alkaloid fumiagoclavine C (221) was obtained from *Aspergillus fumigatus* isolate, and it showed cytotoxicity against the MCF-7 mammary tumor cell line. At a concentration of $20 \mu\text{M}$, this alkaloid demonstrated 93% and 89% ability of reducing the proliferation of these cancer cells after 24 and 36 h, respectively. Compound 221 has also been proven to




Fig. 25. Structures of quinones 174–182.

block the migration and invasion of the cancer cells by modulating the apoptotic protein expressions. Furthermore, fumigaclavine C (221) was revealed to down-regulate the NF-kappa-B cell survival pathway [124]. Tryprostins A (222) and B (223) were discovered in the fermentation extract of the isolate *Aspergillus fumigatus* BM939, obtained from deep-sea sediment and demonstrated an inhibitory growth towards the mouse thermo-sensitive tsFT210 cell line [125]. In another study, alkaloid 222 revealed an ability to be a BCRP inhibitor agent. It also revealed inhibition of the human MCF-7 with an IC₅₀ value of 0.013 ± 0.006 μM [126].

Cui and his coworkers isolated the pentacyclic-type 2, 5-diketopiperazines named cyclotryptostatins A-D (224–227) (Fig. 32) from the marine isolate *Aspergillus fumigatus* BM939. Compounds 224–227 showed inhibition of the cell cycle progression towards mouse tsFT210 cells in the G₂/M phase with IC₅₀ values of 5.6, 19.5, 23.4, and 25.3 μM, respectively [127]. Luteoalbusins A (228) and B (229), T988A (230), along with gliocladiines C (231) and D (232) were isolated from the deep-sea marine fungus *Acrostalagmus luteoalbus* SCSIO F457. Alkaloids 228–232 showed cytotoxic effects towards MCF-7 exhibiting IC₅₀ values ranging from 0.91 to 0.25 μM [128]. *Arthrinium* sp., produced pyridone alkaloid arthpyrone L (233) and displayed cytotoxic effects towards MCF-7 and MDA-MB-231 with IC₅₀: 14.0 and 21.3 μM respectively [129]. Penochalasin I (234), penochalasin J (235), chaetoglobosins A (236), C (237), F (238), G (239), and cytoglobosin C (240) were produced by *Penicillium chrysogenum* and possessed cytotoxic effects

towards MDA-MB-435 with IC₅₀ ranging from 7.5 to 38.7 μM respectively [130].

5.3. Quinones

2-Methoxyjuglone (241) and penithoketone (242) (Fig. 33) were isolated from *Penicillium thomii* and illustrated cytotoxic effects against MCF-7 with IC₅₀: 11 and 21 μM, respectively. In addition, quinones 241 and 242 were active against and MDA-MB-468 with IC₅₀: 15 and 4.9 μM, respectively [131]. Alterporriol K (243) and L (244) are bianthraquinones, isolated from the marine-derived fungus *Alternaria* sp. and both natural products possessed cytotoxic effects against MDA-MB-435 and MCF-7 with IC₅₀: ranging from 13.1 to 29.1 μM [132]. SZ-685 C (245) is an anthraquinone obtained from the endophytic fungus No. 1403 found in deep-sea mangroves. This compound showed inhibition of the proliferation of MCF-7 and MDA-MB-435 with IC₅₀: 7.5 and 3.0 μM respectively [133].

5.4. Meroterpenes

Epoxyphomalins A (246) and B (247) (Fig. 34) are meroterpenoids, produced by marine-derived fungus *Phoma* sp. They displayed cytotoxicity against 401NL and MCF-7 cell lines with IC₅₀ values of 0.010 and 0.116 μg/mL and 0.501 and 0.398 μg/mL, respectively [134]. Aszonapyrone A (248) and sartorypyrone B (249) were obtained from the




Fig. 26. Structures of compounds 183–189.




Fig. 27. Structures of compounds 190–196.

derived-marine fungus *Neosartorya laciniosa*. Both compounds revealed *in vitro* inhibitory effects towards MCF-7 with a GI₅₀ of 13.6 and 17.8 μM, respectively [135]. Purpurogemutantin (250) and purpurogemutantidin (251) are additional meroterpenoids that were reported from the marine-derived fungal strain *Penicillium purpurogenum* G59 isolated from the soil sample from Bohay Bay, Tianjin, China. Compounds 250 and 251 were active against the MCF-7 with IC₅₀: 29.3 and 26.3 μM, respectively [136]. Acremochlorin A (252), E-G (253–255), K-M (256–258), and meroterpenoids 259–269 were produced by fungus *Acremonium sclerotigenum*. All compounds demonstrated cytotoxicity towards MDA-MB-231 and MDA-MB-468 with IC₅₀ ranging from 0.65 to 57.0 μM. Notably compound 252 possessed potent effects towards both cancer cells with IC₅₀ < 1 μM [137].

5.5. Miscellaneous

Isosclerone (270) (Fig. 35) is a pentaketide metabolite, that was obtained from the marine-derived *Aspergillus fumigatus*. At a concentration of 60 μM, compound 270 showed significant cytotoxic activity against the human breast malignancy MCF-7 cells after 24 h incubation and subsequently leading to apoptosis. Investigating its mechanism of action revealed that this compound blocked the MAPK pathway, inhibiting ERK, JNK, and P38 phosphorylation. It has also proven to be responsible for down-regulation of CDK and cyclin proteins and up-regulating the p53 at transcriptional level [138].

Monacolin X (271) is a polyketide isolated from the marine-derived fungus *Monascus* sp. NMK7 spores accumulated on the surface of (*Clathria frondifera*) sponge. This compound exhibited magnificent




Fig. 28. Structures of compounds 197–199.

cytotoxicity effect towards MCF-7, T47D, MDA-MB-231, and MDA-MB-468 cells, displaying IC₅₀ values of 42.8, 33.9, 48.7 and 26.3 μM, respectively [139]. Pericosine A (272) is a shikimate derivative obtained from the marine fungal strain *Periconia byssoides*. Compound 272 showed potent growth inhibition towards HBC-5 with log GI₅₀: 5.2 [140]. Terrein (273) was isolated from the diverse marine fungus *Aspergillus terreus* [141] and illustrated cytotoxicity towards MCF-7 with an IC₅₀ value of 1.1 nM [142].

Marthiapeptide (274) is a cyclic peptide, containing a sequential trithiazole-thiazoline segment, obtained from a strain of the marine fungus *Marinactinopora thermotolerance SCSIO 00652*. Compound 274 efficiently reduced the growth of MCF-7 with an IC₅₀ value of 0.38 μM [143]. Varitriol (275), isolated from the marine fungus strain *Emericella variecolor* collected in Venezuelan waters of the Caribbean Sea, displayed a great potency towards the T-47D breast cancer cell line showing a GI₅₀ value of 2.10×10^{-7} M [144]. Monalbidins C and D (276 and 277), monacolin K methyl ester (278), dehydromonacolin L (279), dehydromonacolin K (280), and O-acetylmonacolin K (283) which were reported from marine derived fungus *Monascus albidus*, possessed moderate cytotoxicity towards MDA-MB-231 with IC₅₀: 9.3–41.6 μM. On the other hand monacolin K (282) showed better effects with 9.3–3.7 μM [145]. In another study, ganodermasides A (284), B (285) were isolated from fungus *Pseudogymnoascus* sp. and possessed cytotoxicity towards MDA-MB-231 with IC₅₀: 30.0 and 27.0 μM respectively [146]. Moreover, 5, R,6 S,16 R, 3E)-5,6-dihydroxy-16-methoxyhexadec-3-en-2-one (286) and bekeleylactone E (287) were produced by fungus *Aspergillus flocculosus* and showed cytotoxicity towards MDA-MB-231 with GI₅₀: 2.4 and 3.1 μM respectively [147].

Polyketide, RF-3192 C (288) was reported from *Aspergillus niger* and showed cytotoxic effect towards MCF-7 with IC₅₀: 47 μM [148]. Ter-saphilones B (289), D (290), E (291), luteusin A (292), luteusin C (293) and RP-1551-5 (294) (Fig. 36) were isolated from fungus *Phomopsis tersa* and compounds 290–292 and 294 possessed good cytotoxicity towards MCF-7 with IC₅₀ < 10 μM. On the other hand compounds 289 and 293 showed moderate and weak effects with IC₅₀: 13 and 25.5 μM respectively [149]. Pensulfonamide (295) was produced by fungus *Penicillium aculeatum* and displayed significant cytotoxicity towards MCF-7 with IC₅₀: 2.18 μM [150]. Three pairs of new salicylaldehyde derivative enantiomers, euroticins F (296), I (297), and eurotirumin (298) were reported from fungus *Eurotium* sp. and demonstrated cytotoxicity towards MCF-7 with IC₅₀ ranging from 20.5 to 55.5 μM [151].


6. Soft coral

Pseudopterosin (299) (Fig. 37) is a glycosidic terpene isolated from the marine-derived soft coral *Pseudopterogorgia elisabethae*, collected from the Caribbean ocean [152]. It exerts its activity by hindering cytokine discharge in triple-negative breast cancer (TNBC), resulting in a delay of the NF-κB signal. Compound 299 revealed cytotoxicity against MDA-MB-231 with an IC₅₀ value of 24.4 μM [153]. Cembrane diterpenes 300 and 301 were isolated from the soft coral *Sarcophyton ehrenbergi* while the cembrane analog 302 was isolated from another soft coral *Nephthea* sp. Compounds 300–302 demonstrated cytotoxicity effects MCF-7 with GI₅₀: 6.1, 1.7, and 0.15 μg/mL, respectively [154].

Sarcocrassocolides A–D (303–306) [155] and crassocolides A, B and D–F (307–311) along with lobophytolide (312) [156] (Fig. 38) are cembranoid diterpenes isolated from the marine soft coral *Sarcophyton crassocaule* collected off Taiwan. Diterpenes 303–306 exhibited cytotoxicity towards MCF-7 with ED₅₀ values of 4.2, 3.2, 2.0, and 4.1 μg/mL, respectively [155]. Compounds 307–311, which possesses a *trans*-fused α-methylene γ-lactone moiety, displayed moderate cytotoxicity towards MCF-7 and MDA-MB-231 with IC₅₀ ranging from 2.0 to 15.3 μg/mL [156]. Lobophytolide (312) was the most active compound against MDA-MB-231 and MCF-7 with IC₅₀: 2.0 and 2.3 μg/mL, respectively [156].

Sardigitolide B (313) (Fig. 39) represents a new biscembranoidal metabolite isolated from the culture broth of the marine soft coral *Sarcophyton digitatum*. This metabolite illustrated cytotoxicities toward MDA-MB-231 and MCF-7 with the IC₅₀: 14.8 and 9.6 μg/mL, respectively [157]. Protoxenincins A (314) and B (315) are new xenicanes (bicyclic diterpenoids featuring a cyclononane) that were isolated from the soft coral *Protodendron repens*, collected off the coast of Okuza. Compounds 314 and 315 displayed cytotoxic activities against MDAMB-231 with GI₅₀ value of 2.1 and 6.3 μM, respectively [158].

Sarcodictyins A (316) and sarcodictyin B (317) [159] are diterpenoids, isolated from the soft coral *Eleutherobia aurea* while eleutherobin (318), a glycoside analog was isolated from the soft coral *Eleutherobia* species [160]. This latter compound has proven to be more effective against MCF-7 with an IC₅₀ value of 10 nM which is greater than compounds 316 and 317 which displayed IC₅₀ values of 400 and 300 nM, respectively [161]. Waixenicin A (319) is a diterpenoid (aTRPM7 Inhibitor) isolated from the marine soft coral *Sarcothelia edmondsoni*, collected off the Hawaiian coast. It showed cytotoxicity towards MCF-7 cells, with an IC₅₀ value of 4.6 μM [162].

**Fig. 29.** Structures of compounds 200–210.




Fig. 30. Structures of sesquiterpenes and sesterterpenes 211–215.




Fig. 31. Structures of alkaloids 216–223.

Three sesquiterpenes, aromadendrene (320), palustrol (321), viridiflorol (322), two diterpenes, xeniolide I (323), xeniolide O (324), and two steroids, 23,24-dimethylcholest-16-ene-3 β ,5 α ,6 β ,20(R)-tertrol 3-monoacetate (325), and gorgst-3 β ,5 α ,6 β ,11 α ,20(S)-pentol-3-monoacetate (326) were reported from soft coral *Xenia umbellata*. All these compounds showed cytotoxicity towards MCF-7 with IC₅₀ ranging from 1.5 to 19.1 μ g/mL. Notably compounds 1 and 6 possessed significant cytotoxicity with IC₅₀: 1.7 and 1.5 μ g/mL respectively [163] (Table 5).

7. Sea cucumbers

Argusides B-E (327–330) (Fig. 40) are holostane-type triterpene glycosides, isolated from the sea cucumber *Bohadschia argus* [164,165]. Compounds 327 and 328 showed potent cytotoxicity against the MCF-7 with IC₅₀: 1.64 and 1.55 μ M, respectively [164] while argusides 329 and 330 exhibited good cytotoxicity against MCF-7 with IC₅₀: 7.7, and 7.5 μ M (Table 6), respectively [165]. Scbraside D (331), fuscocineroside C (332) and 24-dehydroechinoside A (333) are also holostane-type triterpenoid glycosides isolated from the sea cucumber *Holothuria scabra*. All three compounds 331–333 showed cytotoxicity towards the

MCF-7 with IC₅₀ values of 1.80, 2.60, and 1.79 μ M, respectively [166]. Frondoside A (334) is triterpenoid a glycoside, found in the sea cucumber *Cucumaria frondosa* and illustrated anticancer towards the MDA-MB-231 and MCF10-A, MDA-MB-435, MCF-7 with an IC₅₀ value of 1.2, 5.0, 2.5, and 2.0 μ M, respectively [167]. Holospiniferoside (335), a ceramide was produced by ea Cucumber *Holothuria spinifera* and this molecules displayed cytotoxicity towards MCF-7 with IC₅₀: 20.6 μ M [168].

8. Mollusks

Prosobranch mollusks of the genus *Lamellaria* yielded a family of pyrrole alkaloids named lamellarin D (336) (Fig. 41) which displayed cytotoxicity towards MCF-7 cells with an IC₅₀ value of 100 nM [169]. Pterocellins A (337) and B (338) are alkaloids isolated from the marine bryozoan *Pterocella vesiculosa*. Compound 337 possessed cytotoxicity towards MDA-MB-231 and MCF-7 with GI₅₀: 2.6 and 1.5 μ M μ M, respectively. Similarly compound 338 inhibited the proliferation of MCF-7, and MDA-MB-231 cells with GI₅₀: 1.0 and 3.3 μ M, respectively [170].

Kahalalide F (339) (Fig. 42) is a natural depsipeptide, isolated from


Table 4
Metabolites 211–298 having anti-breast cancer properties.

| Name | Organism | Cell line | Cytotoxicity | Ref. | |
|--|--|----------------------|---|---------------------------------|-------|
| Coriolin B (211) | <i>Jaspis aff. Johnstoni</i> | T-47D | IC ₅₀ : 0.7 μM | [117] | |
| Neomangicols A (212) | <i>Fusarium equiseti</i> CNC-477 | MCF-7 | IC ₅₀ : 4.9 μM | [118] | |
| Neomangicols B (213) | <i>Fusarium equiseti</i> CNC-477 | MCF-7 | IC ₅₀ : 27 μM | [118] | |
| Ophiobolin O (214) | <i>Aspergillus ustus</i> fungal | MCF-7 | IC ₅₀ : 17.8 μM | [119] | |
| 9α,14-Dihydroxy-6β-p-nitrobenzoylcinnamolide (215) | <i>Aspergillus versicolor</i> CNC 327 | BT-549 | LC ₅₀ : 0.27 μg/mL | [120] | |
| Avrainvillamide (216) | <i>Avrainvillaea</i> sp. | BT-549 | IC ₅₀ : 34 nM | [121] | |
| | | T-47D | IC ₅₀ : 72 nM | | |
| Acetylapoaranotin (217) | <i>Aspergillus</i> sp. | MCF-7 | IC ₅₀ : 10 μM | [122] | |
| Acetylalarotin (218) | <i>Aspergillus</i> sp. | MCF-7 | IC ₅₀ : 36 μM | [122] | |
| Deoxyapoaranotin (219) | <i>Aspergillus</i> sp. | MCF-7 | IC ₅₀ : 31 μM | [122] | |
| Gliotoxin (220) | <i>Aspergillus</i> sp. strain YL-06 | MCF-7 | IC ₅₀ : 985 nM | [123] | |
| | | T47D | IC ₅₀ : 365 nM | | |
| | | BT-474 | IC ₅₀ : 102 nM | | |
| | | ZR75-1 | IC ₅₀ : 158 nM | | |
| | | MDA-MB231 MDA-MB435 | IC ₅₀ : 138 nM | | |
| | | | IC ₅₀ : 87 nM | | |
| Fumigaclavine C (221) | <i>Aspergillus fumigatus</i> | MCF-7 | Inhibition: 93% | [124] | |
| Tryprostatins A (222) | <i>Aspergillus fumigatus</i> BM939 | MCF-7 | IC ₅₀ : 0.013 μM | [126] | |
| Tryprostatins B (223) | <i>Aspergillus fumigatus</i> BM939 | tsFT210 | IC ₅₀ : 12.5 μg/mL | [125] | |
| Cyclotryprostatin A (224) | <i>Aspergillus fumigatus</i> BM939 | tsFT210 | IC ₅₀ : 5.6 μM | [127] | |
| Cyclotryprostatin B (225) | <i>Aspergillus fumigatus</i> BM939 | tsFT210 | IC ₅₀ : 19.5 μM | [127] | |
| Cyclotryprostatin C (226) | <i>Aspergillus fumigatus</i> BM939 | tsFT210 | IC ₅₀ : 23.4 μM | [127] | |
| Cyclotryprostatin D (227) | <i>Aspergillus fumigatus</i> BM939 | tsFT210 | IC ₅₀ : 25.3 μM | [127] | |
| Luteoalbusin A (228) and B (229), T988A (230), gliocladienes C (231) and D (232) | <i>Acrostalagmus luteoalbus</i> SC510 F457 | MCF-7 | IC ₅₀ : 0.91–0.25 μM | [128] | |
| Arthpyrone L (233) | <i>Arthrinium</i> sp. | MCF-7 | IC ₅₀ : 14.0 μM | [129] | |
| | | MDA-MB-231 | IC ₅₀ : 21.3 μM | | |
| Penochalasin I (234) | <i>Penicillium chrysogenum</i> | MDA-MB-231 | IC ₅₀ : 7.5 μM | [130] | |
| Penochalasin J (235) | <i>Penicillium chrysogenum</i> | MDA-MB-231 | IC ₅₀ : 36.6 μM | [130] | |
| Chaetoglobosin A (236) | <i>Penicillium chrysogenum</i> | MDA-MB-231 | IC ₅₀ : 37.5 μM | [130] | |
| Chaetoglobosin C (237) | <i>Penicillium chrysogenum</i> | MDA-MB-231 | IC ₅₀ : 19.9 μM | [130] | |
| Chaetoglobosin F (238) | <i>Penicillium chrysogenum</i> | MDA-MB-231 | IC ₅₀ : 37.7 μM | [130] | |
| Chaetoglobosin G (239) | <i>Penicillium chrysogenum</i> | MDA-MB-231 | IC ₅₀ : 38.7 μM | [130] | |
| Cytiglobosin C (240) | <i>Penicillium chrysogenum</i> | MDA-MB-231 | IC ₅₀ : 12.5 μM | [130] | |
| 2-Methoxyjuglone (241) | <i>Penicillium thomii</i> | MCF-7 | IC ₅₀ : 11 μM | [131] | |
| | | MDA-MB-468 | IC ₅₀ : 4.9 μM | | |
| Penithoketone (242) | <i>Penicillium thomii</i> | MCF-7 | IC ₅₀ : 21 μM | [131] | |
| | | MDA-MB-468 | IC ₅₀ : 15 μM | | |
| Alterporriol K (243) | <i>Alternaria</i> sp. | MCF-7 and MDA-MB-435 | IC ₅₀ : 13.1–29.1 μM | [132] | |
| Alterporriol L (244) | <i>Alternaria</i> sp. | MCF-7 and MDA-MB-435 | IC ₅₀ : 13.1–29.1 μM | [132] | |
| SZ-685 C (245) | Fungus No. 1403 | MCF-7 | IC ₅₀ : 7.5 μM | [133] | |
| | | MDA-MB-435 | IC ₅₀ : 3 μM | | |
| Epoxyphomalins A (246) | <i>Phoma</i> sp. | MCF-7 | IC ₅₀ : 0.116 μg/mL | [134] | |
| Epoxyphomalins B (247) | <i>Phoma</i> sp. | MCF-7 | IC ₅₀ : 0.398 μg/mL | [134] | |
| Aszonapyrone A (248) | <i>Neosartorya laciniosa</i> | MCF-7 | GI ₅₀ : 13.6 μM | [135] | |
| Sartorypyrone B (249) | <i>Neosartorya laciniosa</i> | MCF-7 | GI ₅₀ : 17.8 μM | [135] | |
| Purpurogemutantin (250) | <i>Penicillium purpurogenum</i> G59 | MCF-7 | IC ₅₀ : 29.3 μM | [136] | |
| Purpurogemutantidin (251) | <i>Penicillium purpurogenum</i> G59 | MCF-7 | IC ₅₀ : 26.3 μM | [136] | |
| Acremochlorin A (252) | <i>Acremonium sclerotigenum</i> | MDA-MB-231 | IC ₅₀ : 0.65 μM | [137] | |
| | | MDA-MB-468 | IC ₅₀ : 0.48 μM | | |
| Acremochlorin E (253) | <i>Acremonium sclerotigenum</i> | MDA-MB-231 | IC ₅₀ : 45 μM | [137] | |
| | | MDA-MB-468 | IC ₅₀ : 34 μM | | |
| Acremochlorin F (254) | <i>Acremonium sclerotigenum</i> | MDA-MB-231 | IC ₅₀ : 41 μM | [137] | |
| | | MDA-MB-468 | IC ₅₀ : 15 μM | | |
| Acremochlorin G (255) | <i>Acremonium sclerotigenum</i> | MDA-MB-231 | IC ₅₀ : 25 μM | [137] | |
| | | MDA-MB-468 | IC ₅₀ : 26 μM | | |
| Acremochlorin K (256) | <i>Acremonium sclerotigenum</i> | MDA-MB-231 | IC ₅₀ : 3.3 μM IC ₅₀ : 1.7 μM | [137] | |
| | | MDA-MB-468 | IC ₅₀ : 12 μM; | | |
| Acremochlorin L (257) | <i>Acremonium sclerotigenum</i> | MDA-MB-231 | IC ₅₀ : 7.5 μM | [137] | |
| | | MDA-MB-468 | IC ₅₀ : 7.4 μM IC ₅₀ : 6 μM | | |
| Acremochlorin M (258) | <i>Acremonium sclerotigenum</i> | MDA-MB-231 | MDA-MB-468 | IC ₅₀ : 0.65–57.0 μM | [137] |
| Meroterpenoids (259–269) | <i>Acremonium sclerotigenum</i> | MDA-MB-231 | MDA-MB-468 | | |
| Isosclerone (270) | <i>Aspergillus fumigatus</i> | MCF-7 | Inhibition %: 50–97 | [138] | |
| Monacolin X (271) | <i>Monascus</i> sp. NMK7 | MCF-7 | IC ₅₀ : 42.8 μM | [139] | |
| | | T47D | IC ₅₀ : 33.9 μM | | |
| | | MDA-MB-231 | IC ₅₀ : 48.7 μM | | |
| | | MDA-MB-468 | IC ₅₀ : 26.3 μM | | |
| Pericosine A (272) | <i>Periconia byssoides</i> | HBC-5 | GI ₅₀ : 5.2 μM | [140] | |
| Terrein (273) | <i>Aspergillus terreus</i> | MCF-7 | IC ₅₀ : 1.1 nM | [141, 142] | |

(continued on next page)

Table 4 (continued)

| Name | Organism | Cell line | Cytotoxicity | Ref. |
|--|--|------------|--|-------|
| Marthiapeptide (274) | <i>Marinactinopora thermotolerance SCSIO 00652</i> | MCF-7 | IC ₅₀ : 0.38 μM | [143] |
| Varitriol (275) | <i>Emericella varicolor</i> | T-47D | GI ₅₀ : 2.10 × 10 ⁻⁷ M | [144] |
| Compounds 276–283 | <i>Monascus albidus</i> | MDA-MB-231 | IC ₅₀ : 9.3–41.6 μM | [145] |
| Ganodermaside A (284) | <i>Pseudogymnoascus sp.</i> | MDA-MB-231 | IC ₅₀ : 30.0 μM | [146] |
| Ganodermaside B (285) | <i>Pseudogymnoascus sp.</i> | MDA-MB-231 | IC ₅₀ : 27.0 μM | [146] |
| 5 R,6 S,16 R,3E)-5,6-Dihydroxy-16-methyloxacyclohexadec-3-en-2-one (286) | <i>Aspergillus flocculosus</i> | MDA-MB-231 | GI ₅₀ : 2.4 μM | [147] |
| Bekeleylactone E (287) | <i>Aspergillus flocculosus</i> | MDA-MB-231 | GI ₅₀ : 2.4–3.1 μM | [147] |
| RF-3192 C (288) | <i>Aspergillus niger</i> | MCF-7 | IC ₅₀ : 47 μM | [148] |
| Tersaphilone B (289) | <i>Phomopsis teresa</i> | MCF-7 | IC ₅₀ : 13 μM | [149] |
| Tersaphilone D (290) | <i>Phomopsis teresa</i> | MCF-7 | IC ₅₀ : 7.8 μM | [149] |
| Tersaphilone E (291) | <i>Phomopsis teresa</i> | MCF-7 | IC ₅₀ : 5.4 μM | [149] |
| luteusin A (292) | <i>Phomopsis teresa</i> | MCF-7 | IC ₅₀ : 2.8 μM | [149] |
| luteusin C (293) | <i>Phomopsis teresa</i> | MCF-7 | IC ₅₀ : 25.5 μM | [149] |
| RP-1551-5 (294) | <i>Phomopsis teresa</i> | MCF-7 | IC ₅₀ : 3.1 μM | [149] |
| Pensulfonamide (295) | <i>Penicillium aculeatum</i> | MCF-7 | IC ₅₀ : 2.18 μM | [150] |
| (+)-Euroticin F (296) | <i>Eurotium sp.</i> | MCF-7 | IC ₅₀ : 27.1 μM | [151] |
| (-) Euroticin F (296) | <i>Eurotium sp.</i> | MCF-7 | IC ₅₀ : 28 μM | [151] |
| (+)-Euroticin I (297) | <i>Eurotium sp.</i> | MCF-7 | IC ₅₀ : 20.5 μM | [151] |
| (-) Euroticin I (297) | <i>Eurotium sp.</i> | MCF-7 | IC ₅₀ : 23.5 μM | [151] |
| (+)-Eurotirumin (298) | <i>Eurotium sp.</i> | MCF-7 | IC ₅₀ : 55.5 μM | [151] |
| (-) Eurotirumin (298) | <i>Eurotium sp.</i> | MCF-7 | IC ₅₀ : 50.6 μM | [151] |

**Fig. 32.** Structures of alkaloids 224–240.




Fig. 33. Structures of quinones 241–245.




Fig. 34. Structures of meroterpenoids 246–269.




Fig. 35. Structures of compounds 270–287.




Fig. 36. Structures of compounds 288–298.




Fig. 37. Structures of compounds 299–302.




Fig. 38. Structures of compounds 303–312.




Fig. 39. Structures of compounds 313–326.

Table 5
Metabolites 299–326 having anti-breast cancer properties.

| Name | Organism | Cell line | Cytotoxicity | Ref. |
|---|--------------------------------------|------------|-----------------------------------|-----------|
| Pseudopterosin (299) | <i>Pseudopterogorgia elisabethae</i> | MDA-MB-231 | IC ₅₀ : 24.4 μM | [153] |
| Diterpene 300 | <i>Sarcophyton ehrenbergi</i> | MCF-7 | GI ₅₀ : 6.1 μg/mL | [154] |
| Diterpenes 301 | <i>Sarcophyton ehrenbergi</i> | MCF-7 | GI ₅₀ : 1.7 μg/mL | [154] |
| Cembrane diterpene 302 | <i>Nephthea sp</i> | MCF-7 | GI ₅₀ : 0.15 μg/mL | [154] |
| Sarcocassicolide A (303) | <i>Sarcophyton crassocaule</i> | MCF-7 | ED ₅₀ : 4.2 μg/mL | [155] |
| Sarcocassicolide B (304) | <i>Sarcophyton crassocaule</i> | MCF-7 | ED ₅₀ : 3.2 μg/mL | [155] |
| Sarcocassicolide C (305) | <i>Sarcophyton crassocaule</i> | MCF-7 | ED ₅₀ : 2.0 μg/mL | [155] |
| Sarcocassicolide D (306) | <i>Sarcophyton crassocaule</i> | MCF-7 | ED ₅₀ : 4.1 μg/mL | [155] |
| Crassocolides A, B, D-F (307–311) | <i>Sarcophyton crassocaule</i> | MCF-7 | IC ₅₀ : 2.0–15.3 μg/mL | [156] |
| Lobophytolide (312) | <i>Sarcophyton crassocaule</i> | MDA-MB-231 | IC ₅₀ : 2.0 μg/mL | [156] |
| Sardigitolide B (313) | <i>Sarcophyton digitatum</i> | MCF-7 | IC ₅₀ : 2.3 μg/mL | [157] |
| Protoxenicin A (314) | <i>Protodendron repens</i> | MDAMB-231 | IC ₅₀ : 9.6 μg/mL | [158] |
| Protoxenicin B (315) | <i>Protodendron repens</i> | MDAMB-231 | IC ₅₀ : 14.8 μg/mL | [158] |
| Sarcodictyin A (316) | <i>Eleutherobia aurea</i> | MCF-7 | IC ₅₀ : 2.1 μM | [158] |
| Sarcodictyins B (317) | <i>Eleutherobia aurea</i> | MCF-7 | IC ₅₀ : 6.3 μM | [158] |
| Eleutherobin (318) | <i>Eleutherobia species</i> | MCF-7 | IC ₅₀ : 400 nM | [160,161] |
| Waixeninic A (319) | <i>Sarcothelia edmondsoni</i> | MCF-7 | IC ₅₀ : 300 nM | [160,161] |
| Aromadendrene (320) | <i>Xenia umbellata</i> | MCF-7 | IC ₅₀ : 10 nM | [162] |
| Palustrol (321) | <i>Xenia umbellata</i> | MCF-7 | IC ₅₀ : 4.6 μM | [162] |
| Viridiflorol (322) | <i>Xenia umbellata</i> | MCF-7 | IC ₅₀ : 1.7 μg/mL | [163] |
| Xeniolide I (323) | <i>Xenia umbellata</i> | MCF-7 | IC ₅₀ : 7.5 μg/mL | [163] |
| Xeniolide O (324) | <i>Xenia umbellata</i> | MCF-7 | IC ₅₀ : 2.4 μg/mL | [163] |
| 23,24-Dimethylcholest-16-ene-3β,5α,6β,20(R)-tertrol 3-monoacetate (325) | <i>Xenia umbellata</i> | MCF-7 | IC ₅₀ : 18.2 μg/mL | [163] |
| Gorgst-3β,5α,6β,11α,20(S)-pentol-3-monoacetate (326) | <i>Xenia umbellata</i> | MCF-7 | IC ₅₀ : 23.2 μg/mL | [163] |
| | <i>Xenia umbellata</i> | MCF-7 | IC ₅₀ : 1.5 μg/mL | [163] |
| | <i>Xenia umbellata</i> | MCF-7 | IC ₅₀ : 19.1 μg/mL | [163] |

the Hawaiian marine mollusk *Elysia rufescens* [171] and illustrated potent cytotoxicity against SKBR-3, BT474 & MCF-7 cell lines with IC₅₀ values of 0.23, 0.26 and 0.28 μM, respectively [172]. Dolastatin 19 (340) is a macrocyclic lactone isolated from the marine mollusk *Dolabella auricularia* collected from the Gulf of California. Compound 340 inhibited the proliferation of MCF-7 with GI₅₀: 0.72 μg/mL [173].

9. Tunicates and Sea pen

Lissoclinotoxins E (341) and F (342) (Fig. 43) are dimeric polysulfide alkaloids isolated from a didemnid ascidian of the genus *Lissoclinum* collected from Philippines. Compounds 341 and 342 showed cytotoxic effects towards MDA-MB-468, with IC₅₀: 2.3 and 1.5 μg/mL, respectively [174]. Indolocarbazole alkaloids 343 and 344 were obtained from marine ascidian *Cystodytes solitus*. Both alkaloids 343 and 344 reduced the proliferation of the MDA-MB-231 with GI₅₀ 28.4 and 32.1 nM, respectively [175]. Aplidine (345) is a cyclic depsipeptide which was reported from the *Aplidium albicans* and is now in phase II clinical trials. This interesting compound displayed efficient activity towards the MDA-MB-231 human mammary cell line with an IC₅₀ value of 5 nM [176]. Metabolites 346–348 were isolated from the marine-derived Sea pen, *Virgularia gustaviana* and showed an anti-proliferative effect against MDA-MB-231 with IC₅₀ values of 0.093, 0.42, and 0.024 mg/mL, respectively [177].

Aplicyanins B (349), bromoindole alkaloids, D-F (350–352) were produced by tunicate *Aplidium cyaneum* and all compounds (except compound 351) demonstrated potent cytotoxicities towards MDA-MB-231 with IC₅₀: 0.42, 0.41, and 0.81 μM, respectively [178]. Jimenez et al. [179] reported 2-hydroxy-7-oxostaurosporine (353) and 3-hydroxy-7-oxostaurosporine (354) from tunicate *Eudistoma vannamei* and mixture of these compounds possessed potent cytotoxic effects towards MDA-MB-435 with IC₅₀: 28.6 nM.

10. Starfish

Triterpene glycosides, pacificosides B (355), C (356), cucumariosides C1 (357), C2 (358), and A10 (359) (Fig. 44), were reported from starfish *Solaster pacificus*. Compounds 356–359 possessed significant effects towards MDA-MB-231 with IC₅₀ of 6.4, 3.6, 4.4, and 5.5 μM, respectively. On the other hand, triterpene 355 displayed week effects with IC₅₀ of 21.5 μM [180].

11. Miscellaneous marine sources

Aplysqualenol A (360) (Fig. 45) is a bromotriterpene polyether, that was collected from the Caribbean sea slug *Aplysia dactylomela*, collected off the Puerto Rican coast. Compound 360 displayed a potent inhibitory activity towards the T-47D cell line, with an IC₅₀: 0.3 μg/mL [181]. Halocynthiaxanthin (361) and fucoxanthinol (362) are two carotenoids related to fucoxanthin that were isolated from the *Halocynthia roretzi* sea squirt. Both compounds displayed a decrease in the proliferation of the MCF-7 cells and interestingly, exhibited apoptosis inducing effects [182].

12. Conclusion

Bearing in mind that marine world investigations are really in their infancy stages, the present review confirms that a huge diversity of the marine compounds, structurally unique have clearly illustrated their potential as new anti-breast cancer compounds. Currently, the development of new technologies, especially the new “omics” approaches, which are extremely efficient and sensitive methods to study marine secondary metabolites, combined with genome mining, should contribute to the development of new emerging bioactive compounds having a profound impact on human health, particularly in the fight against breast cancer.


**Fig. 40.** Structures of compounds 327–335.

Table 6

Metabolites 327–366 having anti-breast cancer properties.

| Name | Organism | Cell line | Cytotoxicity | Ref. |
|--|-------------------------------|---|---|-----------|
| Arguside B (327) | <i>Bohadschia argus</i> | MCF-7 | IC ₅₀ : 1.64 μM | [164,165] |
| Arguside C (328) | <i>Bohadschia argus</i> | MCF-7 | IC ₅₀ : 1.55 μM | [164,165] |
| Arguside D (329) | <i>Bohadschia argus</i> | MCF-7 | IC ₅₀ : 7.7 μM | [164,165] |
| Arguside E (330) | <i>Bohadschia argus</i> | MCF-7 | IC ₅₀ : 7.5 μM | [164,165] |
| Scabraside D (331) | <i>Holothuria scabra</i> | MCF-7 | IC ₅₀ : 1.8 μM | [166] |
| Fuscocineroside C (332) | <i>Holothuria scabra</i> | MCF-7 | IC ₅₀ : 2.6 μM | [166] |
| 24-Dehydroechinoside A (333) | <i>Holothuria scabra</i> | MCF-7 | IC ₅₀ : 1.79 μM | [166] |
| Frondoside A (334) | <i>Cucumaria frondosa</i> | MDA-MB-231 and MCF10-A, MDA-MB-435, MCF-7 | IC ₅₀ : 1.2, 5.0, 2.5, and 2.0 μM | [167] |
| Holospiniferoside (335) | <i>Holothuria spinifera</i> | MCF-7 | IC ₅₀ : 20.6 μM | [168] |
| lamellarin D (336) | <i>Lamellaria sp.</i> | MCF-7 | IC ₅₀ : 100 nM | [169] |
| Pterocellin A (337) | <i>Pterocella vesiculosus</i> | MCF-7; MDA-MB-231 | GI ₅₀ : 1.5 μM, and 2.6 μM | |
| Pterocellin B (338) | <i>Pterocella vesiculosus</i> | MCF-7; MDA-MB-231 | GI ₅₀ : 1.0 and 3.3 μM | [170] |
| Kahalalide F (339) | <i>Elysis rufescens</i> | SKBR-3, BT474 & MCF-7 | IC ₅₀ : 0.23, 0.26 and 0.28 μM | [171,172] |
| Dolastatin 19 (340) | <i>Dolabella auricularia</i> | MCF-7 | GI ₅₀ : 0.72 μg/mL | [173] |
| Lissoclinotoxin E (341) | <i>Lissoclinum sp.</i> | MDA-MB-468 | IC ₅₀ : 2.3 μM | [174] |
| Lissoclinotoxin F (342) | <i>Lissoclinum sp.</i> | MDA-MB-468 | IC ₅₀ : 1.5 μM | [174] |
| Alkaloid 343 | <i>Cystodytes solitus</i> | MDA-MB-231 | GI ₅₀ : 28.4 nM, | [175] |
| Alkaloid 344 | <i>Cystodytes solitus</i> | MDA-MB-231 | GI ₅₀ : 32.1 nM | [175] |
| Aplidine (345) | <i>Aplidium albicans</i> | MDA-MB-231 | IC ₅₀ : 5 nM | [176] |
| Compound 346 | <i>Virgularia gustaviana</i> | MDA-MB-231 | IC ₅₀ : 0.093 mg/mL | [177] |
| Compound 347 | <i>Virgularia gustaviana</i> | MDA-MB-231 | IC ₅₀ : 0.42 mg/mL | [177] |
| Compound 348 | <i>Virgularia gustaviana</i> | MDA-MB-231 | IC ₅₀ : 0.024 mg/mL | [177] |
| Aplicyanin B (349) | <i>Aplidium cyaneum</i> | MDA-MD-231 | IC ₅₀ : 0.42 μM | [178] |
| Aplicyanin D (350) | <i>Aplidium cyaneum</i> | MDA-MD-231 | IC ₅₀ : 0.41 μM | [178] |
| Aplicyanin E (351) | <i>Aplidium cyaneum</i> | MDA-MD-231 | IC ₅₀ : 7.9 μM | [178] |
| Aplicyanin F (352) | <i>Aplidium cyaneum</i> | MDA-MD-231 | IC ₅₀ : 0.81 μM | [178] |
| 2-Hydroxy-7-oxostaurosporine (353) and 3-Hydroxy-7-oxostaurosporine (354) | <i>Eudistoma vannamei</i> | MDA-MB-435 | Mixture of 353 and 354: IC ₅₀ : 28.6 nM | [179] |
| Pacificuside B (355) | <i>Eudistoma vannamei</i> | MDA-MB-435 | Mixture of 353 and 354: IC ₅₀ : 28.6 nM. | [179] |
| Pacificuside C (356) | <i>Solaster pacificus</i> | MDA-MB-231 | IC ₅₀ : 21.5 μM | [180]. |
| Cucumariosides C1 (357) | <i>Solaster pacificus</i> | MDA-MB-231 | IC ₅₀ : 6.4 μM | [180]. |
| Cucumariosides C2 (358) | <i>Solaster pacificus</i> | MDA-MB-231 | IC ₅₀ : 3.6 μM | [180]. |
| Cucumariosides A10 (359) | <i>Solaster pacificus</i> | MDA-MB-231 | IC ₅₀ : 4.4 μM | [180]. |
| Aplysquenol A (360) | <i>Aplysia dactylomela</i> | T-47D; IC ₅₀ : 0.3 μM | IC ₅₀ : 5.5 μM | [180]. |




Fig. 41. Structures of compounds 336–338.




Fig. 42. Structures of compounds 339 and 340.




Fig. 43. Structures of compounds 341–354.




Fig. 44. Structures of compounds 355–359.




Fig. 45. Structures of compounds 360–362.

CRediT authorship contribution statement

Amjad Hussain, Hidayat Hussain, Polrat Wilairatana: Conceptualization. X.X.: Writing – original draft preparation. **Amjad Hussain, Marie-Lise Bourguet-Kondracki, Maryam Majeed, Muhammad Ibrahim, Xian-Wen Yang, Ishtiaq Ahmed, Muhammad Ibrahim, Ataf Ali Altaf, Anees Ahmed Khalil, Abdur Rauf, Polrat Wilairatana, Hassan A. Hemeg, Riaz Ullah, Ivan R. Green, Iftikhar Ali, Syed Tasadaque A. Shah Hidayat Hussain:** Writing – review & editing. All authors have read and agreed to the published version of the manuscript.

Conflicts of interest statement

The authors declare no conflict of interest.

Acknowledgements

Muhammad Imran (M.I.) extends his appreciation to the Deanship of Scientific Research at King Khalid University for funding this work through the Large Group Research Project under grant number 34/43 and M.I. also acknowledges the Research Center for Advanced Materials (RCAMS) at King Khalid University, Saudi Arabia for their valuable technical support.

References

- [1] D.J. Newman, G.M. Cragg, Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019, *J. Nat. Prod.* 83 (2020) 770–803.
- [2] C. Alves, J. Silva, S. Pinteus, H. Gaspar, M.C. Alpoim, L.M. Botana, R. Pedrosa, From marine origin to therapeutics: the antitumor potential of marine algae-derived compounds, *Front. Pharmacol.* 9 (2018) 777.
- [3] T.F. Molinski, D.S. Dalisay, S.L. Lievens, J.P. Saludes, Drug development from marine natural products, *Nat. Rev. Drug Discov.* 8 (2009) 69–85.
- [4] C. Jiménez, Marine natural products in medicinal chemistry, *ACS Med. Chem. Lett.* 9 (2018) 959–961.
- [5] C. Lyu, T. Chen, B. Qiang, N. Liu, H. Wang, L. Zhang, Z. Liu, CMNPD: a comprehensive marine natural products database towards facilitating drug discovery from the ocean, *Nucleic Acids Res.* 49 (2021) D509–D515.
- [6] V. Jain, H. Kumar, H.V. Anod, P. Chand, N.V. Gupta, S. Dey, S.S. Kesharwani, A review of nanotechnology-based approaches for breast cancer and triple-negative breast cancer, *J. Control. Release* 326 (2020) 628–647.
- [7] S. Ahmed, H. Mirzaei, M. Aschner, A. Khan, A. Al-Harrasi, H. Khan, Marine peptides in breast cancer: Therapeutic and mechanistic understanding, *Biomed. Pharmacother.* 142 (2021), 112038.
- [8] S. Kalimuthu, J. Venkatesan, S.K. Kim, Marine derived bioactive compounds for breast and prostate cancer treatment: a review, *Curr. Bioact. Compd.* 10 (2014) 62–74.
- [9] K.M. Tabakmeker, V.A. Denisenko, A.G. Guzii, P.S. Dmitrenok, S.A. Dyshlovoy, H.-S. Lee, T.N. Makarieva, Monanchomycin C, A New Pentacyclic Guanidine Alkaloid from the Far-Eastern Marine Sponge *Monanchora pulchra*, *Nat. Prod. Commun.* 8 (2013) 1399–1402.
- [10] H. Sorek, A. Rudi, S. Gueta, F. Reyes, M.J. Martin, M. Aknin, E. Gaydou, J. Vacelet, Y. Kashman, Netamines A–G: seven new tricyclic guanidine alkaloids from the marine sponge *Bienna laboutei*, *Tetrahedron* 62 (2006) 8838–8843.
- [11] S. Shrestha, A. Sorolla, J. Fromont, P. Blancafort, G.R. Flematti, Crambescidin 800, Isolated from the Marine Sponge *Monanchora viridis*, Induces Cell Cycle Arrest and Apoptosis in Triple-Negative Breast Cancer Cells, *Mar. Drugs* 16 (2018) 53.
- [12] T.D. Tran, L.K. Cartner, H.R. Bokesch, C.J. Henrich, X.W. Wang, C. Mahidol, S. Ruchirawat, P. Kittakoop, B.R. O'Keefe, K.R. Gustafson, NMR characterization of rearranged staurosporine aglycone analogues from the marine sponge *Damiria* sp., *Magn. Reson. Chem.* 59 (2021) 534–539.
- [13] C. Chantana, U. Sirion, P. Iawsip, J. Jaratjaroonphong, Short Total Synthesis of (\pm)-Gelliuisine E and 2,3'-Bis(indolyl)ethylamines via PTSA-Catalyzed Transindolylation, *J. Org. Chem.* 86 (2021) 13360–13370.
- [14] P.G. Cruz, J.F.M. Leal, A.H. Daranas, M. Perez, C. Cuevas, On the Mechanism of Action of Dragmacidins I and J: Two New Representatives of a New Class of Protein Phosphatase 1 and 2A Inhibitors, *ACS Omega* 3 (2018) 3760–3767.
- [15] R.J. Capon, C. Peng, Cedric Dooms, Trachycladindoles A–G: cytotoxic heterocycles from an Australian marine sponge, *Trachycladus laevipulifer*, *Org. Biomol. Chem.* 6 (2008) 2765–2771.
- [16] A. Kijjoa, R. Wattanadilok, W. Herz, N. Campos, M.S.J. Nascimento, M. Pinto, Anticancer Activity Evaluation of Kuanoniamines A and C Isolated from the Marine Sponge *Oceanapia sagittaria*, Collected from the Gulf of Thailand, *Mar. Drugs* 5 (2007) 6–22.
- [17] R. Liu, Y. Liu, Y.-D. Zhou, D.G. Nagle, Molecular-Targeted Antitumor Agents. 15. Neolamellarins from the Marine Sponge *Dendrilla nigra* Inhibit Hypoxia-Inducible Factor-1 Activation and Secreted Vascular Endothelial Growth Factor Production in Breast Tumor Cells, *J. Nat. Prod.* 70 (2007) 1741–1745.
- [18] X. Wei, K. Nieves, A.D. Rodríguez, Neopetrosamine A, biologically active bis-piperidine alkaloid from the Caribbean sea sponge *Neopetrosia proxima*, *Bioorg. Med. Chem. Lett.* 20 (2010) 5905–5908.
- [19] K. Suwanborirux, S. Amnuaypol, A. Plubrukarn, S. Pummangura, A. Kubo, C. Tanaka, N. Saito, Chemistry of Renieramycins. Part 3.1 Isolation and Structure of Stabilized Renieramycin Type Derivatives Possessing Antitumor Activity from Thai Sponge *Xestospongia* Species, Pretreated with Potassium Cyanide, *J. Nat. Prod.* 66 (2003) 1441–1446.
- [20] K. Charupant, N. Daikuhara, E. Saito, S. Amnuaypol, K. Suwanborirux, T. Ow, N. Saito, Chemistry of renieramycins. Part 8: Synthesis and cytotoxicity evaluation of renieramycin M-jorunnamycin A analogues, *Bioorg. Med. Chem.* 17 (2009) 4548–4558.
- [21] Z.X. Yang, Y.H. Sun, J.G. He, H. Cao, G.Q. Jiang, Increased activity of CHK enhances the radiosensitivity of MCF-7 breast cancer stem cells, *Oncol. Let.* 10 (2015) 3443–3449.
- [22] D.T. Trang, B.H. Tai, D.T. Hang, P.H. Yen, P.T.T. Huong, N.X. Nham, P.V. Kiem, Chemical Constituents of the Marine Sponge Aaptos aaptos (Schmidt, 1864) and Their Cytotoxic Activity, *Nat. Prod. Commun.* 16 (2021) 1–5.
- [23] R.A. Davis, G.C. Mangalindan, Z.P. Bojo, R.R. Antemano, N.O. Rodriguez, G. P. Concepcion, S.C. Samson, D. De Guzman, L.J. Cruz, D. Tasdemir, Microcionamides A and B, Bioactive Peptides from the Philippine Sponge *Clathria (Thaliasia) abietina*, *J. Org. Chem.* 69 (2004) 4170–4176.
- [24] C. Urda, M. Perez, J. Rodriguez, C. Jiménez, C. Cuevas, R. Fernandez, Pembamide, a N-methylated linear peptide from a sponge *Cribrochalina* sp., *Tetrahedron Lett.* 57 (2016) 3239–3242.
- [25] L. Coello, F. Reyes, M.A.J.S. Martín, C. Cuevas, R. Fernández, Isolation and Structures of Pipecolidopeptides A and B, Cytotoxic Cyclic Depsipeptides from the Madagascan Sponge Homophymia, lamellosa, *J. Nat. Prod.* 77 (2014) 298–303.
- [26] M.R. Brennan, C.E. Costello, S.D. Maleknia, G.R. Pettit, K.L. Erickson, Stylopeptide 2, a Proline-Rich Cyclodecapeptide from the Sponge *Stylotella* sp., *J. Nat. Prod.* 71 (2008) 453–456.
- [27] J.E. Coleman, E.D. de Silva, F. Kong, R.J. Andersen, T.M. Allen, Cytotoxic Peptides from the Marine Sponge *Cymbastela* sp., *Tetrahedron* 51 (1995) 10653–10662.
- [28] E.D. de Silva, D.E. Williams, R.J. Andersen, H. Klix, C.F. Holmes, T.M. Allen, Motuporin, A Potent Protein Phosphatase Inhibitor Isolated from the Papua New Guinea Sponge *Theonella swinhonis* Gray, *Tetrahedron Lett.* 33 (1992) 1561–1564.
- [29] M. Rangel, M.P. Prado, K. Konno, H. Naoki, T. Jereitas, G.M. Machado-Santelli, Cytoskeleton alterations induced by *Geodia corticostylifera* depsipeptides in breast cancer cells, *Peptides* 27 (2006) 2047–2057.
- [30] W.F. Tinto, A.J. Lough, S. McLean, W.F. Reynolds, M. Yu, W.R. Chan, Geodiamicolides H and I, further cyclodepsipeptides from the marine sponge *Geodia* sp., *Tetrahedron* 54 (1998) 4451–4458.
- [31] J. Su, Y. Zhong, L. Zeng, H. Wu, X. Shen, K. Ma, A. New, N-Carboxyindole Alkaloid from the Marine Sponge *Raphisia pallida*, *J. Nat. Prod.* 59 (1996) 504–506.
- [32] K. Deepak, S. Kumari, G. Shailender, R.R. Malla, Marine natural compound cyclo-(L-leucyl-L-prolyl) peptide inhibits migration of triple negative breast cancer cells by disrupting interaction of CD151 and EGFR signaling, *Chem. Biol. Interact.* 315 (2020), 108872.
- [33] J. Sun, W. Cheng, N.J. de Voogd, P. Proksch, W. Lin, Stylassatins B–D, cycloheptapeptides from the marine sponge *Styliissa massa*, *Tetrahedron Lett.* 57 (2016) 4288–4292.

- [34] E.W. Schmidt, C. Raventos-Suarez, M. Bifano, A.T. Menendez, C.R. Fairchild, D.J. Faulkner, Scleritodermin A, a Cytotoxic Cyclic Peptide from the Lithistid Sponge *Scleritoderma nodosum*, *J. Nat. Prod.* 67 (2004) 475–478.
- [35] Y. Liu, R. Liu, S.-C. Mao, J.B. Morgan, M.B. Jekabsons, Y.-D. Zhou, D.G. Nagle, Molecular-Targeted Antitumor Agents. 19. Furospongolide from a Marine *Lendenfeldia* sp. Sponge Inhibits Hypoxia-Inducible Factor-1 Activation in Breast Tumor Cells, *J. Nat. Prod.* 71 (2008) 1854–1860.
- [36] R.D. Charan, T.C. McKee, M.R. Boyd, Thorectandrols A and B, new cytotoxic sesterterpenes from the marine sponge *Thorectandra* species, *J. Nat. Prod.* 64 (2001) 661–663.
- [37] R.D. Charan, T.C. McKee, M.R. Boyd, Thorectandrols C, D, and E, new sesterterpenes from the marine sponge *Thorectandra* s, *J. Nat. Prod.* 65 (2002) 492–495.
- [38] A.-Y. Shin, A. Son, C. Choi, J. Lee, Isolation of Scalarane-Type Sesterterpenoids from the Marine Sponge *Dysidea* sp. and Stereochemical Reassignment of 12-epi-Phyllactone D/E, *Mar. Drugs* 19 (2021) 627.
- [39] A.I. Foudah, S. Jain, B.A. Busnena, K.A. El, Sayed, Optimization of Marine Triterpene Sipholenols as Inhibitors of Breast Cancer Migration and Invasion, *ChemMedChem* 8 (2013) 497–510.
- [40] A. Fontana, M.L. Ciavatta, P. Amodeo, G. Cimino, Single solution phase conformation of new antiproliferative cembranes, *Tetrahedron* 55 (1999) 1143–1152.
- [41] J. Dai, J.A. Fishback, Y.-D. Zhou, D.G. Nagle, Sodwanone, and Yardenone Triterpenes from a South African Species of the Marine Sponge *Axinella* Inhibit Hypoxia-Inducible Factor-1 (HIF-1) Activation in Both Breast and Prostate Tumor Cells, *J. Nat. Prod.* 69 (2006) 1715–1720.
- [42] X.C. Luo, Q. Wang, X.L. Tang, P.L. Li, G.Q. Li, One cytotoxic steroid and other two new metabolites from the South China Sea sponge *Luffariella variabilis*, *Tetrahedron Lett.* 65 (2021), 152762.
- [43] S.P. Ovenden, J.L. Nielson, C.H. Liptrot, R.H. Willis, D.M. Tapiolas, A.D. Wright, C.A. Motti, Metachromins UW: Cytotoxic Merosesquiterpenoids from an Australian Specimen of the Sponge *Thorecta reticulata*, *J. Nat. Prod.* 74 (2011) 1335–1338.
- [44] A.R. Diaz-Marrero, P. Austin, R. Van Soest, T. Matainaho, C.D. Roskelley, M. Roberge, R.J. Andersen, Avinosol, A Meroterpenoid-Nucleoside Conjugate with Antiinvasion Activity Isolated from the Marine Sponge *Dysidea* sp, *Org. Lett.* 8 (2006) 3749–3752.
- [45] F. Marion, D.E. Williams, B.O. Patrick, I. Hollander, R. Mallon, S.C. Kim, D. M. Roll, L. Feldberg, R. Van Soest, R.J. Andersen, Liphagal, A Selective Inhibitor of PI3 Kinase α Isolated from the Sponge *Aka coraliphaga*: Structure Elucidation and Biomimetic Synthesis, *Org. Lett.* 8 (2006) 321–324.
- [46] E. Alvarez-Manzaneda, R. Chahboun, E. Alvarez, M. José Cano, A. Haidour, R. Alvarez-Manzaneda, Enantioselective Total Synthesis of the Selective PI3 Kinase Inhibitor Liphagal, *Org. Lett.* 12 (2010) 4450–4453.
- [47] A. Kijjoa, J. Bessa, R. Wattanadilok, P. Sawangwong, M.S.J. Nascimento, M. Pedro, A.M. Silva, G. Eaton, R. van Soest, W. Herz, DibromoTyrosine Derivatives, a Maleimide, Aplysamine-2 and Other Constituents of the Marine Sponge *Pseudoceratina purpurea*, *Z. Naturforsch. B* 60 (2005) 904–908.
- [48] Y.-D. Zhou, J. Li, L. Du, F. Mahdi, T.P. Le, W.-L. Chen, S.M. Swanson, K. Watabe, D.G. Nagle, Biochemical and anti-triple negative metastatic breast tumor cell properties of psammaphins, *Mar. Drugs* 16 (2018) 442.
- [49] K. Fukuoka, T. Yamagishi, T. Ichihara, S. Nakaike, K. Iguchi, Y. Yamada, H. Fukumoto, T. Yoneda, K. Samata, H. Ikeda, Mechanism of action of aragusterol a (YTA0040), a potent anti-tumor marine steroid targeting the G1 phase of the cell cycle, *Int. J. Cancer* 88 (2000) 810–819.
- [50] R.A. Isbrucker, J. Cummins, S.A. Pomponi, R.E. Longley, A.E. Wright, Tubulin polymerizing activity of dictyostatin-1, a polyketide of marine sponge origin, *Biochem. Pharmacol.* 66 (2003) 75–82.
- [51] A. Chan, P.M. Andreea, P.T. Northcote, J.H. Miller, Peloruside A inhibits microtubule dynamics in a breast cancer cell line MCF-7, *Invest. N. Drugs* 29 (2011) 615–626.
- [52] L.A. Shaala, D.T.A. Youssef, Hemimycalins C-E: Cytotoxic and Antimicrobial Alkaloids with Hydantoin and 2-Iminoimidazolidin-4-one Backbones from the Red Sea Marine Sponge *Hemimycale* sp, *Mar. Drugs* 19 (2021) 691.
- [53] D.T. Hang, D.T. Trang, B.H. Tai, P.H. Yen, V.K. Thu, N.X. Nham, P.V. Kiem, Hippotulosas A-D: four new sesterterpenes from marine sponge *Hippopsgonia fistulosa* Lendenfeld, 1889, *Nat. Prod. Res.* 36 (2022) 5247–5254.
- [54] B.H. Tai, D.T. Hang, D.T. Trang, P.H. Yen, P.T.T. Huong, N.X. Nham, D.C. Thung, D.T. Thao, N.T. Hoai, P.V. Kiem, Conjugated Polyene Ketones From the Marine Sponge *Clathria (Thaliasia) Reinwardti* (Vosmaer, 1880) and Their Cytotoxic Activity, *Nat. Prod. Commun.* 16 (2021) 1–7.
- [55] K. Yong-feng, D. Song, Z. Hong-Jun, G. Jian-Hong, Study on the steroidal constituents of *Phyllosporgia* sp. From the South China Sea, *Nat. Prod. Res. Dev.* 33 (2021) 2053.
- [56] G.-E.F. Abd-Ellatef, O.M. Ahmed, E.S. Abdel-Reheim, A.-H.Z. Abdel-Hamid, *Ulva lactuca* polysaccharides prevent Wistar rat breast carcinogenesis through the augmentation of apoptosis, enhancement of antioxidant defense system, and suppression of inflammation, *Breast Cancer.: Targets Ther.* 9 (2017) 67–83.
- [57] O.S. Vishchuk, S.P. Ermakova, T.N. Zvyagintseva, Sulfated polysaccharides from brown seaweeds *Saccharina japonica* and *Undaria pinnatifida*: isolation, structural characteristics, and antitumor activity, *Carbohydr. Res.* 346 (2011) 2769–2776.
- [58] A.M. Suganya, M. Sanjivkumar, M.N. Chandran, A. Palavesam, G. Emmanuel, Pharmacological importance of sulphated polysaccharide carrageenan from red seaweed *Kappaphycus alvarezzii* in comparison with commercial carrageenan, *Biomed. Pharmacother.* 84 (2016) 1300–1312.
- [59] T.P. Lakshmi, S. Vajravijayan, M. Moumita, N. Sakthivel, K. Gunasekaran, R. Krishna, A novel guaiane sesquiterpene derivative, guai-2-en-10 α -ol, from *Ulva fasciata* Delile inhibits EGFR/PI3K/Akt signaling and induces cytotoxicity in triple-negative breast cancer cells, *Mol. Cell. Biochem.* 438 (2018) 123–139.
- [60] W.M. Alarif, K.O. Al-Footy, M.S. Zubair, M. Halid, Ph, M.A. Ghadourah, S.A. Basaif, S.S. Al-Lihaibi, S.E.N. Ayyad, F.A. Badria, The role of new eudesmane-type sesquiterpenoid and known eudesmane derivatives from the redalgae *Laurencia obtusa* as potential antifungal-antitumour agents, *Nat. Prod. Res.* 30 (2016) 1150–1155.
- [61] J.-A. de la Mare, J.C. Lawson, M.T. Chiwakata, D.R. Beukes, A.L. Edkins, G. L. Blatch, Quinones and halogenated monoterpenes of algal origin show anti-proliferative effects against breast cancer cells in vitro, *Invest. N. Drugs* 30 (2012) 2187–2200.
- [62] K.A. Mohammed, C.F. Hossain, L. Zhang, R.K. Bruick, Y.D. Zhou, D.G. Nagle, Laurenditerpenol, a New Diterpene from the Tropical Marine Alga *Laurencia intricata* that Potently Inhibits HIF-1 Mediated Hypoxic Signaling in Breast Tumor Cells, *J. Nat. Prod.* 67 (2004) 2002–2007.
- [63] K.M. Fisch, V. Böhm, A.D. Wright, G.M. König, Antioxidative Meroterpenoids from the Brown Alga *Cystoseira crinita*, *J. Nat. Prod.* 66 (2003) 968–975.
- [64] X. Xiao, X. Liao, S. Qiu, Z. Liu, B. Du, S. Xu, Paper Synthesis, Cytotoxicity and Apoptosis Induction in Human Tumor Cells by Galaxamide and Its Analogue, *Mar. Drugs* 12 (2014) 4521–4538.
- [65] M.K. Pec, A. Aguirre, K. Moser-Thier, J.J. Fernández, M.L. Souto, J. Dorta, F. Díaz-González, J. Villar, Induction of apoptosis in estrogen dependent and independent breast cancer cells by the marine terpenoid dehydrothrysiferol, *Biochem. Pharmacol.* 65 (2003) 1451–1461.
- [66] V. Pasquet, P. Morisset, S. Ihammouine, A. Chepied, L. Aumailley, J.-B. Berard, B. Serive, R. Kaas, I. Lanneluc, V. Thierry, Antiproliferative Activity of Violaxanthin Isolated from Bioguided Fractionation of *Dunaliella tertiolecta* Extracts, *Mar. Drugs* 9 (2011) 819–831.
- [67] W.H. Gerwick, P.J. Proteau, D.G. Nagle, E. Hamel, A. Blokhin, D.L. Slate, Structure of Curacin A, a Novel Antimitotic, Antiproliferative, and Brine Shrimp Toxic Natural Product from the Marine Cyanobacterium *Lyngbya majuscula*, *J. Org. Chem.* 59 (1994) 1243–1245.
- [68] J.D. White, T.-S. Kim, M. Nambu, Absolute Configuration and Total Synthesis of (+)-Curacin A, an Antiproliferative Agent from the Cyanobacterium *Lyngbya majuscula*, *J. Am. Chem. Soc.* 119 (1997) 103–111.
- [69] Z. Liu, P. Xu, T. Wu, W. Zeng, Microtubule-targeting anticancer agents from marine natural substance, *Anticancer Agents Med Chem.* 14 (2014) 409–417.
- [70] V.K. Veena, K. Kennedy, P. Lakshmi, R. Krishna, N. Sakthivel, Anti-leukemic, anti-lung, and anti-breast cancer potential of the microbial polyketide 2, 4-diacetyl-phloroglucinol (DAPG) and its interaction with the metastatic proteins than the antiapoptotic Bcl-2 proteins, *Mol. Cell. Biochem.* 414 (2016) 47–56.
- [71] R.K. Kim, Y. Suh, K.C. Yoo, Y.H. Cui, E. Hwang, H.J. Kim, J.S. Kang, M.J. Kim, Y. Y. Lee, S.J. Lee, Phloroglucinol suppresses metastatic ability of breast cancer cells by inhibition of epithelial-mesenchymal cell transition, *Cancer Sci.* 106 (2015) 94–101.
- [72] C.S. Kong, J.A. Kim, N.Y. Yoon, S.K. Kim, Induction of apoptosis by phloroglucinol derivative from Ecklonia Cavain MCF-7 human breast cancer cells, *Food Chem. Toxicol.* 47 (2009) 1653–1658.
- [73] S.P. Gunasekera, C.S. Owle, R. Montaser, H. Luesch, V.J. Paul, Malyngamide 3 and Cocosamides A and B from the Marine Cyanobacterium *Lyngbya majuscula* from Cocos Lagoon, Guam, *J. Nat. Prod.* 74 (2011) 871–876.
- [74] J.A.V. Lopez, S.S. Al-Lihaibi, W.M. Alarif, A. Abdel-Lateff, Y. Nogata, K. Washio, M. Morikawa, T. Okino, Wewakazole B, a Cytotoxic Cyanobactin from the Cyanobacterium *Moorea* producens Collected in the Red Sea, *J. Nat. Prod.* 79 (2016) 1213–1218.
- [75] A. Tripathi, J. Puddick, M.R. Prinsep, P.P.F. Lee, L.T. Tan, Hantupeptin A, a Cytotoxic Cyclic Depsipeptide from a Singapore Collection of *Lyngbya majuscula*, *J. Nat. Prod.* 72 (2009) 29–32.
- [76] L. Liu, K.S. Rein, New Peptides Isolated from *Lyngbya* Species: A Review, *Mar. Drugs* 8 (2010) 1817–1837.
- [77] G.G. Harrigan, B.L. Harrigan, B.S. Davidson, A.-D. Kailuins, New Cyclic Acyldepsipeptides from Cultures of a Marine-Derived Bacterium, *Tetrahedron* 53 (1997) 1577–1582.
- [78] I. Bonnard, M. Rolland, J.M. Salmon, E. Debiton, C. Barthomeuf, B. Banaigs, Total Structure and Inhibition of Tumor Cell Proliferation of Laxaphycins, *J. Med. Chem.* 50 (2007) 1266–1279.
- [79] R. Montaser, K.A. Abboud, V.J. Paul, H. Luesch, Pitiprolamide, a Proline-Rich Dolastatin 16 Analogue from the Marine Cyanobacterium *Lyngbya majuscula* from Guam, *J. Nat. Prod.* 74 (2010) 109–112.
- [80] H. Luesch, R. Pangilinan, W.Y. Yoshida, R.E. Moore, V.J. Paul, Pitipeptolides A and B, New Cyclodepsipeptides from the Marine Cyanobacterium *Lyngbya majuscula*, *J. Nat. Prod.* 64 (2001) 304–307.
- [81] R. Montaser, V.J. Paul, H. Luesch, Pitipeptolides C–F, antimycobacterial cyclodepsipeptides from the marine cyanobacterium *Lyngbya majuscula* from Guam, *Phytochemistry* 72 (2011) 2068–2074.
- [82] S.L. Mooberry, R.M. Leal, T.L. Tinley, H. Luesch, R.E. Moore, T.H. Corbett, The molecular pharmacology of symplastostatin 1: A new antimitotic dolastatin 10 analog, *Int. J. Cancer* 104 (2003) 512–521.
- [83] G.R. Pettit, J.C. Knight, D.L. Herald, R.K. Pettit, F. Hogan, V.J. Mukku, J. S. Hamblin, M.J. Dodson, J.C. Chapuis, Antineoplastic Agents. 570. Isolation and Structure Elucidation of Bacillistatin 1 and 2 from a Marine Bacillus silWestris, *J. Nat. Prod.* 72 (2009) 366–371.
- [84] R.A. Medina, D.E. Goeger, P. Hills, S.L. Mooberry, N. Huang, L.I. Romero, E. Ortega-Barria, W.H. Gerwick, K.L. McPhail, Coibamide A, a Potent

- Antiproliferative Cyclic Depsipeptide from the Panamanian Marine Cyanobacterium *Leptolyngbya* sp., J. Am. Chem. Soc. 130 (2008) 6324–6325.
- [85] K. Taori, V.J. Paul, H. Luesch, Structure and Activity of Largazole, A Potent Antiproliferative Agent from the Floridian Marine Cyanobacterium *Symploca* sp., J. Am. Chem. Soc. 130 (2008) 1806–1807.
- [86] W. Wrasielio, A. Mielgo, V.A. Torres, S. Barbero, K. Stoletov, T.L. Suyama, R. L. Klemke, W.H. Gerwick, D.A. Carson, D.G. Stupack, The marine lipopeptide somocystinamide A triggers apoptosis via caspase 8, Proc. Natl. Acad. Sci. U. S. A 105 (2008) 2313–2318.
- [87] T.L. Simmons, K.L. McPhail, E. Ortega-Barría, S.L. Mooberry, W.H. Gerwick, Belamide A, a new antimitotic tetrapeptide from a Panamanian marine cyanobacterium, Tetrahedron Lett. 47 (2006) 3387–3390.
- [88] Z. Guo, S. Ma, S. Khan, H. Zhu, B. Zhang, S. Zhang, R. Jiao, Zhaoshumycins A and B, Two Unprecedented Antimycin-Type Depsipeptides Produced by the Marine-Derived *Streptomyces* sp., ITBB-ZKa6, Mar. Drugs 19 (2021) 624.
- [89] X.-X. Han, C.-B. Cui, Q.-Q. Gu, W.-M. Zhu, H.-B. Liu, J.-Y. Gu, H. Osada, ZHD-0501, a novel naturally occurring staurosporine analog from *Actinomadura* sp. 007, Tetrahedron Lett. 46 (2005) 6137–6140.
- [90] S.-Y. Jeong, H.J. Shin, T.S. Kim, H.-S. Lee, S.-K. Park, H.M. Kim, Streptokordin, a New Cytotoxic Compound of the Methylpyridine Class from a Marine-derived *Streptomyces* sp., KORDI-3238, J. Antibiot. 59 (2006) 234.
- [91] H. Gourdeau, J.B. McAlpine, M. Ranger, B. Simard, F. Berger, F. Beaudry, P. Falardeau, Identification, characterization and potent antitumor activity of ECO-4601, a novel peripheral benzodiazepine receptor ligand, Cancer Chemother. Pharmacol. 61 (2008) 911–921.
- [92] C. Hohmann, K. Schneider, C. Brunntner, E. Irran, G. Nicholson, A.T. Bull, A. L. Jones, R. Brown, J.E. Stach, M. Goodfellow, Caboxamycin, a new antibiotic of the benzoxazole family produced by the deep-sea strain *Streptomyces* sp., NTK 937, J. Antibiot. 62 (2009) 99.
- [93] S. Li, X. Tian, S. Niu, W. Zhang, Y. Chen, H. Zhang, X. Yang, W. Zhang, W. Li, S. Zhang, J. Ju, C. Zhang, Pseudonocardians A-C, New Diazaanthraquinone Derivatives from a Deep-Sea Actinomycete *Pseudonocardia* sp., SCSIO 01299, Mar. Drugs 9 (2011) 1428–1439.
- [94] V.R.R.K. Dasari, M.K.K. Muthyalu, M.Y. Nikku, S.R.R. Donthireddy, Novel Pyridinium compound from marine actinomycete, *Amicolatopsis alba* var. nov. DMR 04 showing antimicrobial and cytotoxic activities in vitro, Microbiol. Res. 167 (2012) 346–351.
- [95] R.P. Maskey, F.C. Li, S. Qin, H.H. Fiebig, H. Laatsch, Chandrananimycins A-C: Production of Novel Anticancer Antibiotics from a Marine *Actinomadura* sp., Isolate M048 by Variation of Medium Composition and Growth Conditions, J. Antibiot. 56 (2003) 622–629.
- [96] J. Bitzer, T. Große, L. Wang, S. Lang, W. Beil, A. Zeeck, New Aminophenoxazinones from a Marine Halomonas sp.: Fermentation, Structure Elucidation, and Biological Activity, J. Antibiot. 59 (2006) 86–92.
- [97] W. Al-Zereini, C.B.F.F. Yao, H. Laatsch, H. Anke, Aqabamycins A-G: novel nitro maleimides from a marine *Vibrio* species: I. Taxonomy, fermentation, isolation and biological activities, J. Antibiot. 63 (2010) 297.
- [98] U.W. Hawas, M. Shaaban, K.A. Shaaban, M. Speitling, A. Maier, G. Kelter, H. H. Fiebig, M. Meiners, E. Helmke, H. Laatsch, Mansouramycins A-D, Cytotoxic Isoquinolinequinones from a Marine Streptomycete, J. Nat. Prod. 72 (2009) 2120–2124.
- [99] R.P. Maskey, E. Helmke, H.H. Fiebig, H. Laatsch, Parimycin: Isolation and Structure Elucidation of a Novel Cytotoxic 2, 3-Dihydroquinizarin Analogue of γ-Indomycinone from a Marine Streptomycete Isolate, J. Antibiot. 55 (2002) 1031–1035.
- [100] G.D. Martin, L.T. Tan, P.R. Jensen, R.E. Dimayuga, C.R. Fairchild, C. Raventos-Suarez, W. Fenical, Marmycins A and B, Cytotoxic Pentacyclic C-glycosides from a Marine Sediment-Derived Actinomycete Related to the Genus *Streptomyces*, J. Nat. Prod. 70 (2007) 1406–1409.
- [101] H. Huang, T. Yang, X. Ren, J. Liu, Y. Song, A. Sun, J. Ma, B. Wang, Y. Zhang, C. Huang, Cytotoxic Angucycline Class Glycosides from the Deep Sea Actinomycete *Streptomyces hispanicus* SCSIO LR32, J. Nat. Prod. 75 (2012) 202–208.
- [102] F. Li, R.P. Maskey, S. Qin, I. Sattler, H.H. Fiebig, A. Maier, A. Zeeck, H. Laatsch, Chinikomycins A and B: Isolation, Structure Elucidation, and Biological Activity of Novel Antibiotics from a Marine *Streptomyces* sp., Isolate M045, J. Nat. Prod. 68 (2005) 349–353.
- [103] T. Furumai, Y. Igarashi, H. Higuchi, N. Saito, T. Oki, Kosinostatin, a Quinocycline Antibiotic with Antitumor Activity from *Micromonospora* sp., TP-A0468, J. ANTIBIOT. 55 (2002) 128–133.
- [104] X. Zhang, C. Song, Y. Bai, J. Hu, H. Pan, Cytotoxic and antimicrobial activities of secondary metabolites isolated from the deep-sea-derived *Actinalloteichus cyanogriseus* 12A22, Biotech 11 (2021) 283.
- [105] T. Furumai, K. Takagi, Y. Igarashi, N. Saito, T. Oki, Arisostatins A and B, New Members of Tetrocarcin Class of Antibiotics from *Micromonospora* sp. TP-A0316, J. Antibiot. 53 (2000) 227–232.
- [106] F.C. Pinto, E.R. Silveira, A.C.L. Vasconcelos, K.G. Florêncio, F.A. Oliveira, B. B. Sahm, L.V. Costa-Lotufo, A. Bauermeister, N.P. Lopes, D.W. Wilke, Dextrorotatory Chromomycins from the Marine *Streptomyces* sp. Associated to *Palythoa caribaeorum*, J. Braz. Chem. Soc. 31 (2020) 143–152.
- [107] A.F. Braña, A. Sarmiento-Vizcaíno, I. Pérez-Victoria, J. Martín, L. Otero, J. J. Palacios-Gutiérrez, J. Fernández, Y. Mohamedi, T. Fontanil, M. Salmón, Desertomycin G, A New Antibiotic with Activity against Mycobacterium tuberculosis and Human Breast Tumor Cell Lines Produced by *Streptomyces althioticus* MSM3, Isolated from the Cantabrian Sea Intertidal Macroalgae *Ulva* sp., Mar. Drugs 17 (2019) 114.
- [108] M. Pérez, C. Crespo, C. Schleissner, P. Rodríguez, P. Zúñiga, F. Reyes, Tartrolon D, A Cytotoxic Macrolide from the Marine-Derived Actinomycete *Streptomyces* sp. MDG-04-17-069, J. Nat. Prod. 72 (2009) 2192–2194.
- [109] A. Dübeler, P. Krastel, H.G. Floss, A. Zeeck, Biosynthesis of the Antibiotic Echinosporin by a Novel Branch of the Shikimate Pathway, Eur. J. Org. Chem. (2002) 983–987.
- [110] R.P. Maskey, E. Helmke, O. Kayser, H.H. Fiebig, A. Maier, A. Busche, H. Laatsch, Anti-cancer and Antibacterial Trioxacarcons with High Anti-malaria Activity from a Marine Streptomycete and their Absolute Stereochemistry, J. Antibiot. 57 (2004) 771–779.
- [111] K. Schneider, S. Keller, F.E. Wolter, L. Rögl, W. Beil, O. Seitz, G. Nicholson, C. Brunntner, J. Riedlinger, H.P. Fiedler, Proximicins A, B, and C—Antitumor Furan Analogues of Netrospin from the Marine Actinomycete *Verrucosporangium* Induce Upregulation of p53 and the Cyclin Kinase Inhibitor p21, Angew. Chem. Int. Ed. 47 (2008) 3258–3261.
- [112] M. Pérez, C. Schleissner, R. Fernández, P. Rodríguez, F. Reyes, P. Zúñiga, F. De, La Calle and C. Cuevas, PM100117 and PM100118, new antitumor macrolides produced by a marine *Streptomyces caniferus* GUA-06-05-006A, J. Antibiot. 69 (2016) 388.
- [113] S. Fu, F. Wang, H. Li, Y. Bao, Y. Yang, H. Shen, B. Lin, G. Zhou, Secondary metabolites from marine-derived *Streptomyces* antibioticus strain H74-21, Nat. - Prod. Res. 30 (2016) 2460–2467.
- [114] K. Moon, C.-H. Ahn, Y. Shin, T.H. Won, K. Ko, S.K. Lee, K.-B. Oh, J. Shin, S.-I. Nam, D.-C. Oh, New Benzoxazine Secondary Metabolites from an Arctic Actinomycete, Mar. Drugs 12 (2014) 2526–2538.
- [115] O.F. Davies-Bolorunduro, I.A. Adeleye, M.O. Akinleye, P.G. Wang, Anticancer potential of metabolic compounds from marine actinomycetes isolated from Lagos Lagoon sediment, J. Pharm. Anal. 9 (2019) 201–208.
- [116] D. Kacar, L.M. Cañedo, P. Rodríguez, E.G. González, B. Galán, C. Schleissner, S. Leopold-Messer, J. Piel, C. Cuevas, F. de la Calle, J.L. García, Identification of trans-AT polyketide clusters in two marine bacteria reveals cryptic similarities between distinct symbiosis factors, Environ. Microbiol. 23 (2021) 2509–2521.
- [117] X.-C. Cheng, M. Varoglu, L. Abrell, P. Crews, E. Lobkovsky, J. Clardy, Chloriolins A-C, Chlorinated Sesquiterpenes Produced by Fungal Cultures Separated from a *Jaspis* Marine Sponge, J. Org. Chem. 59 (1994) 6344–6348.
- [118] M.K. Renner, P.R. Jensen, W. Fenical, Neomangicals: Structures and Absolute Stereochemistries of Unprecedented Halogenated Sesterterpenes from a Marine Fungus of the Genus *Fusarium*, J. Org. Chem. 63 (1998) 8346–8354.
- [119] T. Yang, Z. Lu, L. Meng, S. Wei, K. Hong, W. Zhu, C. Huang, The novel agent ophiobolin O induces apoptosis and cell cycle arrest of MCF-7 cells through activation of MAPK signaling pathways, Bioorg. Med. Chem. Lett. 22 (2012) 579–585.
- [120] G.N. Belofsky, P.R. Jensen, M.K. Renner, W. Fenical, New cytotoxic sesquiterpenoid nitrobenzoyl esters from a marine isolate of the fungus *Aspergillus versicolor*, Tetrahedron 54 (1998) 1715–1724.
- [121] W. Fenical, P.R. Jensen, X.C. Cheng, U.S. (University of California, San Diego, USA). US 6066635, 2000, 6 pp.
- [122] E. Choi, J.S. Park, Y.J. Kim, J.H. Jung, J. Lee, H. Kwon, H. Yang, Apoptosis-inducing effect of diketopiperazine disulfides produced by *Aspergillus* sp. KMD 901 isolated from marine sediment on HCT116 colon cancer cell lines, J. Appl. Microbiol. 110 (2011) 304–313.
- [123] D. Vigushin, N. Mirsaldi, G. Brooke, C. Sun, P. Pace, L. Inman, C. Moody, R. Coombes, Gliotoxin is a dual inhibitor of farnesyltransferase and geranylgeranyltransferase i with antitumor activity against breast cancer in vivo, Med. Oncol. 21 (2004) 21–30.
- [124] Y.-X. Li, S. Himaya, P. Dewapriya, C. Zhang, S.-K. Kim, Fumigaclavine C from a Marine-Derived Fungus *Aspergillus fumigatus* Induces Apoptosis in MCF-7 Breast Cancer Cells, Mar. Drugs 11 (2013) 5063–5086.
- [125] C.-B. Cui, H. Kakeya, G. Okada, R. Onose, M. Ubukata, I. Takahashi, K. Isono, H. Osada, Tryprostins A and B, Novel Mammalian Cell Cycle Inhibitors Produced by *Aspergillus fumigatus*, J. ANTIBIOT. 48 (1995) 1382–1384.
- [126] H. Woehlecke, H. Osada, A. Herrmann, H. Lage, Reversal of breast cancer resistance protein-mediated drug resistance by tryprostatin A, Int. J. Cancer 107 (2003) 721–728.
- [127] C.-B. Cui, H. Kakeya, H. Osada, Novel mammalian cell cycle inhibitors, cycloprotoprostins A-D, produced by *Aspergillus fumigatus*, which inhibit mammalian cell cycle at G2/M phase, Tetrahedron 53 (1997) 59–72.
- [128] F.-Z. Wang, Z. Huang, X.-F. Shi, Y.-C. Chen, W.-M. Zhang, X.-P. Tian, J. Li, S. Zhang, Cytotoxic indole diketopiperazines from the deep sea-derived fungus *Acrostalagmus luteoalbus* SCSIO F457, Bioorg. Med. Chem. Lett. 22 (2012) 7265–7267.
- [129] Y. Zhang, M. Li, Q. Zhang, Z. Wang, X. Li, J. Bao, H. Zhang, Arthpyrone L, a New Pyridone Alkaloid from a Deep-Sea *Arthrinium* sp., Inhibits proliferation of MG63 Osteosarcoma Cells by Inducing G0/G1 Arrest and Apoptosis, Chem. Biodiver. 18 (2021) e2000639.
- [130] S. Huang, H. Chen, W. Li, X. Zhu, W. Ding, C. Li, Bioactive Chaetoglobosins from the Mangrove Endophytic Fungus *Penicillium chrysogenum*, Mar. Drugs 14 (2016) 172.
- [131] Q. Li, W. Xu, R. Fan, J. Zhang, Y. Li, X. Wang, S. Han, W. Liu, M. Pan, Z. Cheng, Penithoketone and Penithochromones A–L, Polyketides from the Deep-Sea-Derived Fungus *Penicillium thomii* YPGA3, J. Nat. Prod. 83 (2020) 2679–2685.
- [132] C.-H. Huang, J.-H. Pan, B. Chen, M. Yu, H.-B. Huang, X. Zhu, Y.-J. Lu, Z.-G. She, Y.-C. Lin, Three Bianthaquinone Derivatives from the Mangrove Endophytic Fungus *Alternaria* sp. ZJ9-6B from the South China Sea, Mar. Drugs 9 (2011) 832–843.

- [133] G. Xie, X. Zhu, Q. Li, M. Gu, Z. He, J. Wu, J. Li, Y. Lin, M. Li, Z. She, SZ-685C, a marine anthraquinone, is a potent inducer of apoptosis with anticancer activity by suppression of the Akt/FOXO pathway, *Br. J. Pharm.* 159 (2010) 689–697.
- [134] I.E. Mohamed, H. Gross, A. Pontius, S. Kehraus, A. Krick, G. Kelter, A. Maier, H.-H. Fiebig, G.M. König, Epoxyphomalin A and B, Prenylated Polyketides with Potent Cytotoxicity from the Marine-Derived Fungus *Phoma* sp. *Org. Lett.* 11 (2009) 5014–5017.
- [135] A. Eamvijarn, N.M. Gomes, T. Dethoup, J. Buaruang, L. Manoch, A. Silva, M. Pedro, I. Marini, V. Roussis, A. Kijjoa, Bioactive meroditerpenes and indole alkaloids from the soil fungus *Neosartorya fischeri* (KUFC 6344), and the marine-derived fungi *Neosartorya laciniosa* (KUFC 7896) and *Neosartorya tsunodae* (KUFC 9213), *Tetrahedron* 69 (2013) 8583–8591.
- [136] S.-M. Fang, C.-B. Cui, C.-W. Li, C.-J. Wu, Z.-J. Zhang, L. Li, X.-J. Huang, W.-C. Ye, Purpurogemutantin and Purpurogemutantidin, New Drimenyl Cyclohexenone Derivatives Produced by a Mutant Obtained by Diethyl Sulfate Mutagenesis of a Marine-Derived *Penicillium purpurogenum* G59, *Mar. Drugs* 10 (2012) 1266–1287.
- [137] X. Luo, G. Cai, Y. Guo, C. Gao, W. Huang, Z. Zhang, H. Lu, K. Liu, J. Chen, X. Xiong, J. Lei, X. Zhou, J. Wang, Y. Liu, Exploring Marine-Derived Ascochlorins as Novel Human Dihydroorotate Dehydrogenase Inhibitors for Treatment of Triple-Negative Breast Cancer, *J. Med. Chem.* 64 (2021), 13918–1393.
- [138] Y.-X. Li, K.-H. Kang, H.J. Kim, S.-K. Kim, In vitro induction of apoptosis by isosclerone from marine-derived fungus *Aspergillus fumigatus*, *Bioorg. Med. Chem. Lett.* 24 (2014) 3923–3927.
- [139] S.N. Nagabhishek, A. Madankumar, A novel apoptosis-inducing metabolite isolated from marine sponge symbiont *Monascus* sp. NMK7 attenuates cell proliferation, migration and ROS stress-mediated apoptosis in breast cancer cells, *RSC Adv.* 9 (2019) 5878–5890.
- [140] T. Yamada, M. Iritani, H. Ohishi, K. Tanaka, K. Minoura, M. Doi, A. Numata, Pericosines, antitumour metabolites from the sea hare-derived fungus *Periconia byssoides*, Structures and biological activities, *Org. Biomol. Chem.* 5 (2007) 3979–3986.
- [141] H.Z. Asfour, Z.A. Awan, A.A. Bagalagel, M.A. Elfaky, R.F.A. Abdelhameed, S. Elhady, Large-Scale Production of Bioactive Terrein by *Aspergillus terreus* Strain S020 Isolated from the Saudi Coast of the Red Sea, *Biomolecules* 9 (2019) 480.
- [142] W.-Y. Liao, C.-N. Shen, L.-H. Lin, Y.-L. Yang, H.-Y. Han, J.-W. Chen, S.-C. Kuo, S.-H. Wu, C.-C. Liaw, Asperjinone, a Nor-Neolignan, and Terrein, a Suppressor of ABCG2-Expressing Breast Cancer Cells, from Thermophilic *Aspergillus terreus*, *J. Nat. Prod.* 75 (2012) 630–635.
- [143] X. Zhou, H. Huang, Y. Chen, J. Tan, Y. Song, J. Zou, X. Tian, Y. Hua, J. Ju, Cyclic Heptaptides, Cordyheptaptides C–E, from the Marine-Derived Fungus *Acremonium persicinum* SCSIO 115 and Their Cytotoxic Activities, *J. Nat. Prod.* 75 (2012) 2251–2255.
- [144] J. Malmström, C. Christophersen, A.F. Barrero, J.E. Oltra, J. Justicia, A. Rosales, Iota-omega Metabolites from a Marine-Derived Strain of the Fungus *Emericella variecolor*, *J. Nat. Prod.* 65 (2002) 364–367.
- [145] Q. Guo, W.J. Lan, L.P. Chen, C.K. Lam, G.K. Feng, R. Deng, X.F. Zhu, H.J. Li, A.-E. Monalibidins, Decalins with Potential Cytotoxic Activities from Marine Derived Fungus *Monascus albidus* BB3, *Chem. Biodivers.* 18 (2021), e2100068.
- [146] T. Shi, X.Q. Li, L. Zheng, Y.H. Zhang, J.J. Dai, E.L. Shang, Y.Y. Yu, Y.T. Zhang, W. P. Hu, D.Y. Shi, Sesquiterpenoids From the Antarctic Fungus *Pseudogymnoascus* sp. HSX2#-11, *Front. Microbiol.* 12 (2021), 688202.
- [147] C.V. Anh, J.S. Kang, B.K. Choi, H.S. Lee, C.S. Heo, H.J. Shin, Polyketides and Meroterpenes from the Marine-Derived Fungi *Aspergillus unguis* 158SC-067 and *A. flocculosus* 01NT-1.5 and Their Cytotoxic and Antioxidant Activities, *Mar. Drugs* 19 (2021) 415.
- [148] M.M. Mahmoud, A.S. Abdel-Razek, A. Hamed, H.S.M. Soliman, L.V. Ponomareva, J.S. Thorson, K.A. Shaaban, M. Shaaban, RF-3192C and other polyketides from the marine endophytic *Aspergillus niger* ASSB4: structure assignment and bioactivity investigation, *Med. Chem. Res.* 30 (2021) 647–654.
- [149] S. Chen, Z. Liu, Y. Chen, H. Tan, H. Liu, W. Zhang, Tersaphilones A–E, cytotoxic chlorinated azaphilones from the deepsea-derived fungus *Phomopsis tersa* FS441, *Tetrahedron* 78 (2021), 131806.
- [150] U.W. Hawas, L.T.A. El-Kassem, E.F. Ahmed, R.A. Alghamdi, Bioactive sulfonyl metabolites from the Red Sea endophytic fungus *Penicillium aculeatum*, *Nat. Prod. Res.* 36 (2022) 2713–2721.
- [151] W.M. Zhong, X.Y. Wei, Y.C. Chen, Q. Zeng, J.F. Wang, X.F. Shi, X.P. Tian, W. M. Zhang, F.Z. Wang, S. Zhang, Structurally Diverse Polycyclic Salicylaldehyde Derivative Enantiomers from a Marine-Derived Fungus *Eurotium* sp. SCSIO F452, *Mar. Drugs* 19 (2021) 543.
- [152] A.M. Mayer, P.B. Jacobson, W. Fenical, R.S. Jacobs, K.B. Glaser, Pharmacological characterization of the pseudopterosins: Novel anti-inflammatory natural products isolated from the Caribbean soft coral, *Pseudopterogorgia elisabethae*, *Life Sci.* 62 (1998) PL401–PL407.
- [153] J. Sperlich, R. Kerr, N. Teusch, The Marine Natural Product Pseudopterosin Blocks Cytokine Release of Triple-Negative Breast Cancer and Monocytic Leukemia Cells by Inhibiting NF-κB Signaling, *Mar. Drugs* 15 (2017) 262.
- [154] H. Gross, S. Kehraus, M. Nett, G.M. König, W. Beil, A.D. Wright, New cytotoxic cembrane based diterpenes from the soft corals *Sarcophyton cherbonnieri* and *Nephthea* sp., *Org. Biomol. Chem.* 1 (2003) 944–949.
- [155] W.-Y. Lin, J.-H. Su, Y. Lu, Z.-H. Wen, C.-F. Dai, Y.-H. Kuo, J.-H. Sheu, Cytotoxic and anti-inflammatory cembranoids from the Dongsha Atoll soft coral *Sarcophyton crassocaule*, *Bioorg. Med. Chem.* 18 (2010) 1936–1941.
- [156] H.-C. Huang, A.F. Ahmed, J.-H. Su, C.-H. Chao, Y.-C. Wu, M.Y. Chiang, J.-H. Sheu, A.-F. Crassocolides, Cembranoids with a trans-Fused Lactone from the Soft Coral *Sarcophyton crassocaule*, *J. Nat. Prod.* 69 (2006) 1554–1559.
- [157] T.-Y. Huang, C.-Y. Huang, C.-H. Chao, C.-C. Lin, C.-F. Dai, J.-H. Su, P.-J. Sung, S.-H. Wu, J.-H. Sheu, New Biscembranoids Sardigitolides A–D and Known Cembranoid-Related Compounds from *Sarcophyton digitatum*: Isolation, Structure Elucidation, and Bioactivities, *Mar. Drugs* 18 (2020) 452.
- [158] C. Urda, R. Fernández, M. Pérez, J. Rodríguez, C. Jiménez, C. Cuevas, Protoxenicins A and B, Cytotoxin Long-Chain Acylated Xenicanes from the Soft Coral *Protodendron repens*, *J. Nat. Prod.* 80 (2017) 713–719.
- [159] S. Ketzinel, A. Rudi, M. Schleyer, Y. Benayahu, Y. Kashman, Sarcodictyin A and Two Novel Diterpenoid Glycosides, Eleutherosides A and B, from the Soft Coral *Eleutherobia aurea*, *J. Nat. Prod.* 59 (1996) 873–875.
- [160] T. Lindel, P.R. Jensen, W. Fenical, B.H. Long, A.M. Casazza, J. Carboni, C. R. Fairchild, Eletherobin, a New Cytotoxin that Mimics Paclitaxel (Taxol) by Stabilizing Microtubules, *J. Am. Chem. Soc.* 119 (1997) 8744–8745.
- [161] E. Hamel, D.L. Sackett, D. Vourloumis, K. Nicolaou, The Coral-Derived Natural Products Eletherobin and Sarcodictyins A and B: Effects on the Assembly of Purified Tubulin with and without Microtubule-Associated Proteins and Binding at the Polymer Taxoid Site, *Biochemistry* 38 (1999) 5490–5498.
- [162] B.J. Kim, J.H. Nam, Y.K. Kwon, I. So, S.J. Kim, The Role of Waxenincin A as Transient Receptor Potential Melastatin 7 Blocker, *Basic Clin. Pharmacol. Toxicol.* 112 (2013) 83–89.
- [163] H.I. Althagbi, F. Budiyanto, A. Abdel-Lateff, K.O. Al-Footy, N.O. Bawakid, M. A. Ghandourah, M.Y. Alfaifi, S.E.I. Elbehairi, W.M. Alarif, Antiproliferative Isoprenoid Derivatives from the Red Sea Alcyonacean *Xenia umbellata*, *Molecules* 26 (2021) 1311.
- [164] B.S. Liu, Y.H. Yi, L. Li, P. Sun, W.H. Yuan, G.Q. Sun, H. Han, M. Xue, Argusides B and C, Two New Cytotoxic Triterpene Glycosides from the Sea Cucumber *Bohadschia argus* Jaeger, *Chem. Biodivers.* 5 (2008) 1288–1297.
- [165] B.S. Liu, Y.H. Yi, L. Li, P. Sun, H. Han, G.Q. Sun, X.H. Wang, Z.L. Wang, Argusides D and E, Two New Cytotoxic Triterpene Glycosides from the Sea Cucumber *Bohadschia argus* Jaeger, *Chem. Biodivers.* 5 (2008) 1425–1433.
- [166] H. Hua, L. Ling, Y.-H. Yi, X.-H. Wang, M.-X. Pan, Triterpene Glycosides from Sea Cucumber *Holothuria scabra* with Cytotoxic Activity, *Chin. Herb. Med.* 4 (2012) 183–188.
- [167] T.E. Adrian, Peter Collin, The Anti-Cancer Effects of Frondoside A, *Mar. Drugs* 16 (2018) 64.
- [168] E.E. Eltamany, U.R. Abdelmohsen, D.M. Hal, A.K. Ibrahim, H.A. Hassanean, R.F. A. Abdelhameed, T.A. Temraz, D. Hajjar, A.A. Makki, O.M. Hendawy, A. M. AboulMagd, K.A. Youssif, G. Bringmann, S.A. Ahmed, Holospiniferoside: A New Antitumor Cerebroside from the Red Sea Cucumber *Holothuria spinifera*: In Vitro and In Silico Studies, *Molecules* 26 (2021) 1555.
- [169] M. Facompré, C. Tardy, C. Bal-Mahieu, P. Colson, C. Perez, I. Manzanares, C. Cuevas, C. Baily, Lamellarin D: A Novel Potent Inhibitor of Topoisomerase I, *Cancer Res* 63 (2003) 7392–7399.
- [170] B. Yao, M.R. Prinsep, B.K. Nicholson, D.P. Gordon, The Pterocellins, Novel Bioactive Alkaloids from the Marine Bryozoan *Pterocella vesiculos*, *J. Nat. Prod.* 66 (2003) 1074–1077.
- [171] M.T. Hamman, C.S. Otto, P.J. Scheuer, D.C. Dunbar, Kahalalides: Bioactive Peptides from a Marine Mollusk *Elysia rufescens* and Its Algal Diet *Bryopsis* sp., *J. Org. Chem.* 61 (1996) 6594–6600.
- [172] Y. Suárez, L. González, A. Cuadrado, M. Berciano, M. Lafarga, A. Muñoz, Kahalalide F, a new marine-derived compound, induces oncosis in human prostate and breast cancer cells, *Mol. Cancer Ther.* 2 (2003) 863–872.
- [173] G.R. Pettit, J.-P. Xu, D.L. Doubek, J.C. Chapuis, J.M. Schmidt, Antineoplastic Agents. 510.1 Isolation and Structure of Dolastatin 19 from the Gulf of California Sea Hare *Dolabella auricularia*, *J. Nat. Prod.* 67 (2004) 1252–1255.
- [174] R.A. Davis, I.T. Sandoval, G.P. Concepcion, R.M. Da Rocha, C.M. Ireland, Lissoclinotoxins E and F, novel cytotoxic alkaloids from a Philippine *Didemnum ascidianum*, *Tetrahedron* 59 (2003) 2855–2859.
- [175] F. Reyes, R. Fernández, A. Rodríguez, S. Bueno, C. de Eguilior, A. Francesch, C. Cuevas, Cytotoxic staurosporines from the marine ascidian *Cystodytes solitus*, *J. Nat. Prod.* 71 (2008) 1046–1048.
- [176] A. Cuadrado, L.F. García-Fernández, L. González, Y. Suárez, A. Losada, V. Alcaide, T. Martínez, J.M. Fernández-Sousa, J.M. Sánchez-Puelles, A. Muñoz, Aplidin™ induces apoptosis in human cancer cells via glutathione depletion and sustained activation of the epidermal growth factor receptor, Src, JNK, and p38 MAPK, *J. Biol. Chem.* 278 (2003) 241–250.
- [177] S. Sharifi, P.G. Mostafavi, R. Tarasi, A.M. Moradi, M.H. Givianrad, M. Farimani, S.N. Ebrahimi, M. Hamburger, H. Niknejad, Purified compounds from marine organism sea pen induce apoptosis in human breast cancer cell MDA-MB-231 and cervical cancer cell Hela, *Eur. J. Pharmacol.* 877 (2020), 173075.
- [178] F. Reyes, R. Fernández, A. Rodríguez, A. Francesch, S. Taboada, C. Ávila, C. Cuevas, Aplicyanins A–F, new cytotoxic bromoindole derivatives from the marine tunicate *Aplidium cyaneum*, *Tetrahedron* 64 (2008) 5119–5123.
- [179] P.C. Jimenez, D.V. Wilke, E.G. Ferreira, R. Takeara, M.O. de Moraes, E.R. Silveira, T.M. da Cruz Lotufo, N.P. Lopes, L.V. Costa-Lotufo, Structure Elucidation and Anticancer Activity of 7-Oxostauroporine Derivatives from the Brazilian Endemic Tunicate *Eudistoma vannamei*, *Mar. Drugs* 10 (2012) 1092–1102.
- [180] T.V. Malyarenko, A.A. Kicha, A.I. Kalinovsky, P.S. Dmitrenok, O.S. Malyarenko, A.S. Kuzmich, V.A. Stonik, N.V. Ivanchina, New Triterpene Glycosides from the

- Far Eastern Starfish *Solaster pacificus* and Their Biological Activity, Biomolecules 11 (2021) 427.
- [181] B. Vera, A.D. Rodríguez, E. Avilés, Y. Ishikawa, Aplysqualenols A and B: squalene-derived polyethers with antitumoral and antiviral activity from the caribbean sea slug *Aplysia dactylomela*, Eur. J. Org. Chem. (2009) 5327–5336.
- [182] I. Konishi, M. Hosokawa, T. Sashima, H. Kobayashi, K. Miyashita, Halocynthiaxanthin and fucoxanthinol isolated from *Halocynthia roretzi* induce apoptosis in human leukemia, breast and colon cancer cells, Comp. Biochem. Physiol. 142 (2006) 53–59.